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ABSTRACT 
One of the major hurdles for therapeutic applications is the efficient delivery of bioactive 
molecules to the site of action. The high flexibility and biosafety of lipid-based nanoparticles 
has greatly enhanced their employment as delivery systems not only for synthetic but also for 
natural molecules such as proteins and nucleic acids. This thesis was brought about to 
investigate the nucleic acid delivery potential of synthetic lipid-based nanoparticles as well as 
to look into the composition and delivery patterns of their natural counterparts, extracellular 
vesicles (EVs), in order to set ground for future lipid-based therapeutic interventions.  
Firstly, in Paper I we explored the potency of a lipid-based delivery agent, Lipofectamine 
2000 which after being frozen and thawed showed orders of magnitude higher nucleic acid 
delivery efficiency in vitro and in vivo than the non-frozen counterpart. This effect was 
consistent across different cryo-manipulations, cell lines and also various types of nucleic 
acid. Further analysis with different methodologies revealed that the underlying potency 
plausibly relies on the elevated sedimentation and spreading of the complexes and/or relates 
to the specific structure or composition of the carrier. These findings illustrate that a simple 
freeze-thawing procedure allows to drastically reduce the amount of transfection reagent for 
cellular nucleic acid delivery, whilst not losing the desired activity. 
Secondly, we shifted our focus to natural lipid-based carriers, EVs in order to shed light on 
the vesicular and non-vesicular (non-EV) small RNA patterns and their relation to the EV 
proteome (Paper II and III). Though the studies exploited different EV enrichment methods 
the relative depletion of vesicular small RNAs was confirmed in both instances. A detailed 
analysis of the secretory repertoire of small RNAs showed a significant depletion of 
microRNA (miRNA) sequences, matching well with the depletion of “miRNA related” 
proteins in EVs. The relative expression level of cellular, EV and non-EV miRNAs correlated 
well and though some differentially expressed (DE) miRNAs were detected, these had a 
relatively low expression in both the source cells as well as in the secretory fractions. We also 
quantified the total level of selected miRNAs in EVs and non-EV fraction investigating both 
the basal as well as overexpressed levels and could verify that the vast majority of mature 
miRNA is secreted to the non-EV portion of the secretome. 
Paper IV was brought about to gain a comprehensive overview of the biodistribution of 
exogenous EVs. This study confirmed that fluorescent lipophilic dyes are suitable for 
membrane labelling and in vivo tracking of EVs. The general biodistribution pattern of EVs 
was seen to follow a common mononuclear phagocytic system (MPS) uptake pattern with the 
majority of EVs accumulating in the liver, spleen and lungs. Nevertheless, depending on the 
cell source, administration route, dose and the presence of targeting moieties this distribution 
could be altered. 
The present findings are important to gain a thorough understanding of the nucleic acid 
delivery capacity of lipid-based nanoparticles, especially EVs and thereby progress their 
employment as therapeutic nucleic acid carriers.  
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INTRODUCTION 
The first reports describing the utility of nucleic acids in modulating gene expression were 
published in late 1970s [1,2]. Though the range and function of nucleic acids was at first 
rather narrow, a remarkable progress in the discovery of new RNA species  together with 
their novel molecular functions has now been made [3–8]. This in turn has urged the 
development of a series of natural or chemically modified nucleic acid molecules, which can 
be harnessed as stand-alone therapeutic entities. Yet, the size and negative charge of nucleic 
acids hinders their passage through the cell membrane, implying to the need of advanced 
carrier systems tailored for their delivery into cells. 
Delivery systems for nucleic acids can broadly be divided into viral and non-viral. The latter 
hold several advantages over viral systems including a higher level of biosafety and an 
improved flexibility to desired modifications. These conditions are met by non-viral lipid-
based delivery systems, many of which are based on natural phospholipids providing a good 
biocompatibility, biodegradability and low immunogenicity compared to viral systems. The 
first generation of lipid-based nucleic acid delivery systems used either anionic or neutral 
lipids, which however were difficult and time consuming to produce [9]. Hence the interest 
was turned towards their cationic versions, which were found to significantly enhance the 
stability of the nucleic acid material as well as, owing to their positive charge, provide an 
improved interaction with the cell membrane [10]. 
Cationic lipids are often mixed with negatively charged nucleic acids to obtain delivery 
complexes known as lipoplexes. Yet, they are more frequently employed for creating 
structured lipoplexes, such as liposomes [11]. To date, a myriad of different cationic lipid-
based transfection reagents have been developed mainly for in vitro screening purposes. The 
discovery of Lipofectin [12] greatly enhanced the use of cationic lipids for nucleic acid 
delivery and ignited the studies of lipid-based nanocarriers also for human gene therapy 
applications [13]. 
In addition to synthetic lipid-based nucleic acid delivery systems, recently an increasing 
interest has been paid to nucleic acid delivery properties of naturally occurring membrane-
enclosed vesicles, called extracellular vesicles (EVs). Though earlier reports of plasma 
membrane derived vesicles exist [14], the first studies on vesicles of endosomal origin were 
published in 1980s [15–17]. Initially, they were thought to purely represent ‘garbage bins’ to 
discard cellular waste [15]. However, a decade later evidence of EV mediated signalling was 
presented [18], opening a brand new research field of intercellular communication. During 
the years thereafter the EV biology field has witnessed an explosive growth, constantly 
revealing new pivotal roles of EVs, disclosing their potential as disease biomarkers as well as 
natural nanoparticles for therapeutic macromolecule delivery. 
This literature review will give a brief overview of lipid-based nucleic acid delivery systems, 
by briefly covering synthetic cationic lipid-based delivery vectors and having an emphasis on 
their natural counterparts, EVs. 
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1 Synthetic cationic lipid-based delivery systems 
1.1 General overview and composition 
The size and negative charge of DNA and RNA hinder their passage through the plasma 
membrane and thereby precludes their naked usage as stand-alone therapeutic compounds. 
Moreover, nucleic acid polymers are susceptible to nucleases present in the biological fluids, 
causing their degradation within minutes [19–21]. Shorter nucleic acid stretches are also 
subject to rapid clearance by renal filtration, significantly decreasing their bioavailability in 
target sites where they additionally face plasma-, endosomal and nuclear membrane barriers 
[22]. As systemic administration of unmodified nucleic acid can furthermore stimulate Toll-
like receptors (TLRs) and thereby activate innate immune response [23], sophisticated 
delivery vehicles that would enhance the bioavailability of nucleic acids are needed.  
The use of cationic lipids for nucleic acid delivery was first described by Felgner et al. in 
1987 [12], reporting a log scale improvement in transfection efficiency as compared to 
conventionally used calcium phosphate or  diethylaminoethyl (DEAE)-dextran mediated gene 
delivery. The general complexation rationale of cationic lipid mediated delivery relies on the 
formation of electrostatic interactions between the positively charged hydrophilic head group 
of the lipid and negatively charged phosphate group of the nucleic acid, whereby neutralizing 
or increasing the overall charge of the complex to aid cellular delivery. Depending on the 
complexation parameters, cationic lipids form highly structured entities or complexes with 
irregular morphology, referred to as liposomes and lipoplexes, respectively [24,25]. In the 
lipoplex, the complexed material is partially condensed and their structure does not resemble 
that of liposomes. Instead, the lipoplex appears as a multilamellar liquid crystal consisting of 
hydrated DNA layers alternating with cationic lipid bilayers [24]. Also, other molecular 
configurations, such as columnar hexagonal phase structures have been described [26]. 
Though the dynamics of lipoplex assembly are poorly understood, it has been shown that 
lipid packaging parameters dictate the organization of the structure [27]. Schematic 
illustration of a lipoplex and a liposome are depicted on Figure 1. 
 
 
 
Figure 1 - Illustration of a multilamellar lipoplex (left) and a spherical liposome (right) encapsulating nucleic 
acid. 
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The first discovery and description of liposomal structures dates back more than 50 years 
when Bangham and colleagues described “bangosomes” [28]. These artificial spherules 
rapidly gained interest and a few years later received a more descriptive term “liposomes” 
[29]. Liposomes are spherical vesicles of 20 nm to a few micrometers in diameter that are 
composed of one or multiple phospholipid bilayers, entrapping a solute of interest. Unlike 
lipoplexes, which most often have an irregular structure, the lipids in liposomes are organized 
in a spherical manner, providing a capsule for the therapeutic moiety. The lipid core protects 
the content from degradation, decreases its cellular toxicity as well as enhances its solubility 
and stability in vivo [30]. In addition, owing to their lipid architecture, liposomes are 
amenable to surface engineering, being beneficiary not only to enhance their uptake, but also 
to introduce specific ligands for improved tissue targeting [31,32]. 
In addition to the aforementioned, cationic lipids are also increasingly used to form lipid 
nanoparticles (LNPs), both for academic studies as well as clinical applications [33,34]. LNPs 
have a similar composition as liposomes, constituting of cationic lipids and helper lipids, yet 
often have a solid, lipophilic core region. The encapsulation of nucleic acids into LNPs is 
usually performed by microfluidic mixing, generating lipid nanostructures containing inner 
inverted micelles of cationic lipids complexed with the nucleic acids [35]. Owing to the 
highly efficient nucleic acid encapsulation, providing the formulation a good potency [36], 
LNPs are one of the most widely used and efficient gene delivery vehicles both for in vitro as 
well as in vivo applications. Moreover, as these nanoparticles allow to simultaneously exploit 
the therapeutic benefits of nucleic acids and encapsulated lipophilic drugs [37], they are also 
at lead among all non-viral delivery vehicles that are used for clinical purposes [34,38]. 
The lipids that are used to form the aforementioned structures can be anionic, neutral or 
cationic. Considering the polyanionic nature of nucleic acids, the use of anionic lipids has 
rather been directed towards the delivery of other therapeutic macromolecules [39]. Well-
characterized and widely used cationic lipids for cellular delivery purposes include [1,2-bis 
(oleoyloxy)-3-(trimethylammonio)propane] (DOTAP) [40], N-[1-(2,3-dioleyloxy)propyl]-
N,N,N-trimethylammonium chloride (DOTMA) [12] and 3β[N-(N′, N′-
dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) [41]. Occasionally, these lipids are 
used as solitary nucleic acid carriers, although most often they are mixed with neutral helper-
lipids (e.g. 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE), 
dioleoylphosphocholine (DOPC) and cholesterol) [12,42] to enhance membrane fusion and 
aid endosomal escape[42]. Though the basic structure of these lipids mimics chemical and 
physical attributes of biological lipids, structural differences in the size of the head group and 
length of the hydrocarbon tail give distinct characteristics to the complex, affecting cellular 
association and uptake. 
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1.2 Uptake and cargo release 
For the complexes to be efficiently taken up by the cells, a high extent of condensation as 
well as a net positive charge is preferred. The interaction of anionic liposomes with cell 
membrane is somewhat unclear, however it has been demonstrated that the uptake will take 
place once a certain threshold of cell-to-liposome charge ratio is exceeded [43]. Cationic 
complexes are known to electrostatically interact with the negatively charged glycoproteins 
and proteoglycans on the cell membrane, thereby facilitating cellular interaction and 
membrane transversal via endocytosis [44,45].  
It is known that larger lipoplexes enter the cells more easily than smaller ones due to their 
improved sedimentation [46], facilitated membrane contact/fusion and easier dissociation of 
the complex after successful endocytosis [47,48]. By increasing the cationic lipid nucleic acid 
ratio, larger lipoplexes with a higher positive net charge can be created.  Yet, too high 
concentration of lipids interferes with the functions of the cellular and subcellular 
membranes, thereby compromising cellular integrity and causing cytotoxicity [49]. In 
addition, even at non-cytotoxic concentrations, the surface charge of the complexes itself can 
cause genotoxic events and lead to the significant formation of micronuclei in cells [50,51]. 
In order to result in successful nucleic acid delivery, the complexes face a rate-limiting step 
of endosomal escape and cargo release from the lipid material. Firstly, it must be noted that 
the majority of the endocytosed material gets targeted to lysosomal degradation [52,53], the 
remainder needs to cause a transient destabilization of the bilayered lipid structure of the 
endosome and reach the site-of-action. The cargo release is often promoted by the 
incorporation of helper-lipids, which not only facilitate interaction with the cell membrane 
but owing to their fusogenic properties also mediate endosomal escape [42,54,55]. In 
addition, it has been hypothesized that the buffering capacity of nanoparticles prevents 
acidification of endosomal vesicles, thereby activating the influx of protons and counterions, 
causing osmotic swelling and rupture of the endosome and cargo release into the cytoplasm. 
However, the so-called “proton sponge” effect is still a matter of active debate [56]. The 
dissociation of nucleic acid from cationic lipoplexes in not fully understood, though it has 
been suggested that charge neutralization and structural changes (phase evolution of lipoplex 
lipids) induced by the interaction with cellular anionic lipids are decisive for a successful 
outcome [57–59].  
Larger lipoplexes are generally only beneficial for in vitro settings, as an improved in vivo 
delivery is commonly obtained with small particles being less prone to clearance by the MPS 
responsible for the elimination of foreign material [60]. Also, the positive surface charge, 
being beneficiary for improved cellular delivery, could lead to a reduction in circulation half-
life and thereby inversely affect the transfection efficiency in vivo [61,62].  This is partly 
attributed to aggregation of the complexes with negatively charged serum proteins as well as 
hemagglutination with erythrocytes [63] leading to their fast clearance from the circulation 
and limiting their usage beyond vascular endothelial cells [64]. To avoid these processes, the 
surface of liposomes and LNPs is often shielded by polymers, such as polyethylene glycol 
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(PEG) or glycolipids (e.g. gangliosides) which provide a neutral hydrophilic layer avoiding 
vesicle aggregation, thereby increasing the circulation time and decreasing immune response 
in vivo [65–68]. Formation of this hydrating layer by the association of the ethylene glycol 
units of PEG and water molecules hinders protein adsorption and subsequent clearance of the 
complexes by the MPS, providing the complexes a so-called “stealth” behaviour [67,69]. 
 
1.3 Commercial lipid-based delivery agents 
Owing to the rapid, scalable and highly reproducible manufacturing process, long shelf-life 
and ease of handling, commercial lipid based reagents have proved themselves as robust 
means of gene delivery, especially for in vitro screening purposes. Their applicability has 
prospered largely owing to the accompanying development of assay-based reporter gene 
systems providing a quick and easy readout to the biological questions of interest. 
The pioneering commercial reagents consisted of well-known lipids (e.g. DOTAP, DOTMA, 
DC-Chol), exhibited rather good transfection efficiencies in different cell models, yet were 
relatively ineffective for in vivo applications (reviewed in [70]). One of the earliest and most 
widely used transfection reagent to date is Lipofectin [12]. This proprietary blend of 
DOTMA/DOPE at 1:1 molar ratio was launched in late 1980s and is considered as one of the 
first lipid-based transfection reagents, which boosted the employment of lipid-based 
nanocarriers not only for in vitro but also for in vivo purposes. Lipid mixtures have thereafter 
been constantly improved, by modifying the head group size or hydrocarbon tail length, 
giving distinct characteristics to the lipoplex regarding association and uptake into the cell. 
To date, a series of transfection reagents have been launched, tailored for the transfection of 
specific types of nucleic acids or cells, formulated for improved gene delivery in vivo or 
serving as broad spectrum delivery agents. The majority of them are proprietary lipid-based 
blends, which can form complexes with the nucleic acid via a simple co-incubation. Since 
commercial lipid mediated transfection gives highly reproducible results and high 
transfection efficiency [71], initial screening purposes are now devoid of the need for specific 
instruments and specialized personnel hampering the wide-spread employment of earlier lipid 
formulations.  
The choice of a commercial reagent largely depends on the delivered macromolecule (DNA, 
RNA or protein) and the type of cell that needs to be transfected (adherent, suspension, 
primary). The vast majority of commercial reagents have been developed for the delivery of 
exogenous nucleic acids, with a range of distinct formulations fine-tuned for each of their 
subtypes (plasmids, oligonucleotides, messenger RNA (RNA), small interfering RNA 
(siRNA) etc.). Yet, broad spectrum transfection reagents (e.g. Lipofectamine 2000 (LF2000)) 
in terms of cell- and macromolecule type are generally more popular, excluding the need to 
handle diverse protocols. 
Owing to the vast number of commercial lipid-based reagents available, detailed dissection of 
their types and properties is out of the scope of this review. The choice of the reagent depends 
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on the research question and specific experiments in mind. Depending on the required 
transfection efficiency or sensitivity of the downstream analysis, screening of many products 
for optimal results might be required. Nevertheless, due to the high cost, such experiments are 
mostly limited to small-scale in vitro screenings, leaving extensive in vitro as well as in vivo 
studies still relying on the usage of custom-made formulations. 
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2 Natural delivery vectors - extracellular vesicles 
 
Despite the vast developmental efforts, the transfection efficiency of synthetic lipid-based 
systems still succumbs to natural carriers. Though synthetic vectors commonly need novel 
interventions to overcome cellular barriers, natural delivery systems have already developed 
several of these merits during the course of their evolution. 
EVs are known for their native ability to cross biological barriers. Owing to their high 
potency to enter cells together with the susceptibility to membrane- or content modifications, 
EVs have drawn increasing attention as natural delivery vectors for different biologics. The 
first report, later acknowledged as describing EVs, outlined the isolation of a “clotting factor” 
in plasma which pelleted at high-speed centrifugation and modulated the clotting time [72]. 
Yet, it took more than two decades until additional studies on cell-derived vesicles were 
published [14,73,74]. At first, these vesicles were collectively referred to as “exosomes”, a 
term initially proposed by Trams et al. in 1981 [75]. Yet, at the time the subcellular origin of 
these vesicles was still unclear. The endolysosomal EV biogenesis pathway was elucidated a 
couple of years later when two groups, investigating the recycling of transferrin receptor, 
demonstrated the release of EVs from multivesicular bodies (MVBs) in two papers published 
only a week apart from each other [15,76].  Thereafter, the term “exosomes” was revived [17] 
and gained a wider acceptance in the scientific community. Nevertheless, EV research was 
largely neglected until 1996 when Raposo et al. [18] described the communication between B 
cell-derived EVs and T cells, indicating to the functional role of EVs in cell-to-cell 
communication. The next big milestones in EV-research denote the discoveries of EV-
mediated transfer of functional RNA between cells [77,78] as well as across the blood-brain-
barrier [79]. The latter further escalated the interest in EVs and opened novel avenues for 
their employment as therapeutic nucleic acid carriers. 
 
2.1 EV terminology and classification 
EVs have attracted interest in disparate research fields, which on one hand has allowed a 
quick reveal of a myriad of biological roles, on the other hand, led to a “stretched” 
terminology as well as lack of standardization and consensus among researchers [80]. 
Several different names for EVs have been proposed, relating them to their specific functions 
(e.g. “tolerosomes” that induce immunological tolerance to dietary antigens [81] or 
“oncosomes” [82] shedded by tumours), or the cell of origin like “prostasomes” [83] (prostate 
epithelial cell vesicles) and “epididymosomes” (deriving from epididymal epithelial cells) 
[84]. As these are only suitable within specialized research fields, commonly a definition 
based on biogenesis, distinguishing between exosomes, microvesicles (MVs) and apoptotic 
bodies, is used. Exosomes are referred to as vesicles that are generated via intraluminal 
budding of the early endosome and secretion to the extracellular space by the fusion of the 
MVB with the plasma membrane. Microvesicles, on the contrary, are mostly referred to as 
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vesicles that directly bud from the cell membrane [85]. In addition to biogenesis, these 
subtypes also differ in size, exosomes ranging from 30-120 nm and microvesicles typically 
between 100-1000 nm [86]. Moreover, also apoptotic bodies are considered as one of the 
subgroup of EVs [87]. These vesicles are typically bigger than MVs (1000-5000 nm), 
originate from plasma membrane budding and/or endoplasmatic reticulum (ER) and often 
contain nuclear fragments [88–90]. 
In addition to aforementioned, also physical characteristics such as density and/or necessary 
pelleting force are used to distinguish the different EV classes [80,91–93]. Yet, all these 
approaches should rather be considered complementary to each other and demand additional 
biochemical analysis in order to provide a detailed characterization of the preparation. 
Considering the disorder in the nomenclature, together with the evidence of size, density and 
surface marker overlap between the EV subgroups [94,95], it has now been widely 
acknowledged that secreted membrane vesicles should collectively be referred to as 
extracellular vesicles [80]. Furthermore, an increasing number of studies are characterizing 
different EV subpopulations with inherent physical characteristics, RNA content and protein 
repertoire [96–99], indicating to the need of an even more sophisticated nomenclature to 
cover the differences. All this contributes to confusion in data interpretation and comparison 
between studies, yet important steps towards an improvement in the nomenclature and 
experimental settings have been made [80,100]. Here, I use the generic term EV to refer to all 
cell-derived membrane enclosed vesicles (except for apoptotic bodies). Depending on the 
importance to the specific context, exosomes and MVs might be named separately. 
 
2.2 EV isolation 
EVs are most commonly purified from conditioned cell culture medium or from biological 
fluids such as urine, blood, cerebrospinal fluid or saliva with the composition of the material 
greatly outlining the obstacles and choice of EV isolation methodology. All these fluids are 
highly complex and in addition to EVs, also contain non-vesicular macromolecules (proteins, 
nucleic acids), cell debris as well as apoptotic- and lipoprotein particles. Hence, the isolation 
of EVs is technically challenging not only due to their size and heterogeneity but also due to 
the multifaceted nature of the surroundings. 
2.2.1 Consideration of the starting material  
For cell culture derived material, the biggest concern is the presence of “additional” vesicles, 
originating from apoptotic cells, fetal bovine serum (FBS) or arising from other media 
supplements. These co-purifying vesicles might mimic the effect of cell derived EVs and 
thereby pose a risk of introducing false positive results. 
Cell debris and apoptotic particles are largely removed by sequential centrifugation steps at 
300 × g and 2,000-3,000 × g, respectively. To minimize the number of FBS-derived particles, 
it is advised to propagate the cells either in serum free conditions or in EV-depleted FBS 
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[101], through phenotypic changes of the source cells must also be considered [102]. Of note, 
in addition to particulate matter, FBS also contains a vast amount of proteins as well as 
diverse repertoire of RNA species, which cannot fully be eliminated and might lead to 
misinterpretation of the data [103,104]. Hence, even though the cell culture environment is 
rather defined, several different factors can affect the final outcome of the study, emphasizing 
the need of controlling and tailoring also in vitro conditions. 
Biological fluids are even more complex than the defined environment of cell culture 
material, demanding individual approaches to yield EV preparations largely free from 
contaminating particulates, proteins and RNA. For example, in plasma, it has been estimated 
that as much as 95-99% of that extracellular RNA is not bound to EVs but rather to proteins 
(e.g. Argonaute 2 (AGO 2) [105]) and lipoprotein particles [106,107] representing potential 
co-isolates for EV preparations [108,109]. In addition, blood borne material is viscous and 
rich in “sticky” proteins such as albumin, posing further challenges to obtain a clean 
preparation and emphasizing the importance of tailored EV enrichment methods. 
Below, a brief overview of the most widely applied EV isolation methods is provided with an 
emphasis on ultracentrifugation (UC) and size exclusion chromatography (SEC) owing to 
their employment in the constitutive papers. 
2.2.2 Ultracentrifugation 
To date, the method with the longest track record and widest application for EV isolation is 
UC. This involves a series of centrifugation steps, whereby the cell debris and apoptotic 
particles are first pelleted at 300 × g and 2,000-3,000 × g, respectively followed by an 
optional centrifugation at 10,000-20,000 × g to remove bigger EVs, often referred to as MVs. 
In order to further enrich for the presence of smaller vesicles the latter step can be substituted 
or followed by a sterile 0.22 µm filtration continued by UC at 100,000-120,000 × g to collect 
particles usually referred to as exosomes [110]. The purity of the preparation can further be 
enhanced by an additional wash step or density gradient separation that separates EVs based 
on their buoyant density and helps to additionally reduce protein contamination [111]. Yet, 
the process is time consuming, unsuitable for high-throughput analysis and is most practical 
as a follow-up method, since particles with a similar density to EVs cannot be discriminated 
[109]. 
Despite the wide employment of UC purification for cell culture derived- as well as 
biological material [112], recent evidence outlines a number of shortcomings (e.g. 
compromised purity, aggregation, decreased vesicle intactness) related to the methodology, 
resulting in a decreased functionality [113] and altered biodistribution in vivo [114]. 
Therefore, increasing efforts have been made to develop “milder” purification strategies with 
improved capacity to retain the biophysical properties of EVs. 
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2.2.3 Size exclusion based methods 
The employment of SEC for EV purification is increasingly practiced and promoted by the 
EV community. The principle of SEC relies on the fractionation of particles by size, 
transiently trapping smaller molecules in porous beads, whereas larger ones bypass the matrix 
and elute earlier [115,116]. Owing to the lack of high g force and extended sample handing 
time, SEC results in improved integrity, purity and functionality of the vesicles compared to 
UC [113,117,118], is less operator dependent as well as shows consistent recovery rates 
across isolations [114]. In addition, SEC allows a fine fractionation of the whole secretome 
[119], remaining largely out of reach with centrifugation based approaches. Also, the method 
can be tailored by the type of gel matrix, pore size and column length to either perform 
routine vesicle preparations up until sophisticated studies on EV subpopulations [98,120]. As 
the pre-packed gravity flow columns are also commercially available, SEC has gained 
increasing popularity as a rapid EV isolation technique. Yet, the methodology is still 
somewhat constrained in its scalability, limiting its employment for large-scale in vivo studies 
as well as engagement in clinical applications. To overcome this drawback, SEC is often 
combined with filtration-based techniques [114], enabling the processing of large sample 
quantities while retaining the benefits of SEC regarding the yield, purity and biophysical 
properties of EVs. 
Another size exclusion based techniques that has rapidly gained popularity is a commercially 
available tangential flow filtration (TFF) system. The TFF method is based on a cross-flow 
filtration process through a semi-permeable membrane filtration unit which has a fixed 
molecular weight cut-off (MWCO) limit. The pores allow the passage of small molecules 
through the membrane, while the larger ones are entrapped and remain in the circulation. 
Simultaneously with the size separation, the method allows to obtain a highly concentrated 
EV sample, being especially valuable for downstream applications such as SEC [121].  
2.2.4 Alternative EV isolation approaches 
In addition to centrifugation and size-based isolation methods a large variety of approaches 
making use of the molecular, biophysical or biochemical characteristics of EVs have been 
developed. Some utilize the surface markers of EVs, such as immunoaffinity capture-based 
techniques and have proven to be useful if only a subtype of EVs is aimed to be investigated 
[103,122]. Others employ polyanions, such as heparin to capture the full diversity of different 
EV types [123]. In addition, several magnetic isolation techniques [124] as well as a plethora 
of lab-on-chip devices have been developed [124,125], with newer approaches opening 
avenues for cancer diagnostics [126]. To prepare EV samples in a simple and quick manner, 
some methodologies take advantage of the change in EV solubility and employ hydrophilic 
polymer solutions such as PEG or commercial polymer-based preparations (e.g. 
ExoQuick™). As the purity of such isolates is rather poor [127], the usage of these methods 
beyond rapid EV assessment is rather limited. Yet, in clinical settings the purity and essence 
of the active component might be less important, permitting a successful employment of 
precipitation based protocols for EV therapeutics [128]. 
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In conclusion, the complexity and variety of EV sources is the main driving force for the 
development of novel isolation methodologies. Biological samples are much more complex, 
heterogeneous and in limited quantities compared to cell-culture derived material, restraining 
the choice of potential purification methods and often resulting in a low amount of EVs. On 
the other hand, cell-culture preparations are more uniform, but need scalable isolation 
methods and might be influenced by culture additives which could skew the biological 
outcome. Hence, the type of purification method to use is highly dependent on the origin of 
the sample as well as the type and extent of downstream analysis. 
 
2.3 EV characterization 
The insufficient understanding of basic EV biology is a major limiting factor for describing 
the identity of the isolated vesicles. Therefore, the International Society for Extracellular 
Vesicles (ISEV) has released a number of position papers providing guidelines and 
describing the minimal experimental requirements for the definition of vesicular preparations 
[100,129,130]. These suggest the characterization of EV size and density, vesicle 
morphology as well as the analysis of EV-associated proteins as discussed hereafter. 
2.3.1 Physical characterization  
The most basic parameters for the characterization of EV preparations include the description 
of size and morphology of the vesicles. In the early studies, these characteristics were 
evaluated by transmission electron microscopy (TEM) [17], which is still the most widely 
used methodology for morphological characterization and is at times operated at cryogenic 
conditions to better preserve the native state of the material [131]. Newer microscopy 
techniques such as atomic force microscopy (AFM)  are less used, yet also allow to measure 
the sample in their native condition, output a three dimensional topography of the material 
and are able to yield quantitative information on surface proteins [132].  
Though microscopy techniques also enable the determination of particle size, the process of 
obtaining such data is rather tedious and limited in the number of representative events. 
Hence, several newer methodologies such as nanoparticle tracking analysis (NTA) [133] and 
tunable resistive pulse sensing (TRPS) [134] have been developed. However, the outcome of 
such technologies greatly relies on the EV isolation methods as contaminating particulate 
material (e.g. lipoproteins) cannot be discriminated from EVs. 
In addition to size and morphology, it is advised that EVs are also characterized by their 
density, ranging around 1.13- 1.19 g/ml in sucrose or iodixanol gradients [135]. Owing to the 
capability to form iso-osmotic solutions at a wide range of densities together with the 
decreased sedimentation time for separation [135], iodixanol (commercially known as 
OptiPrep™) is increasingly employed for density based EV analysis. Yet, the lack of 
standardization of density gradient centrifugation protocols causes slightly variable results 
between different studies. In addition, the method does not allow for the distinction of certain 
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contaminants e.g. high-density lipoproteins from EVs [109], illustrating the importance of 
tailored EV isolation approaches.  
2.3.2 Molecular characterization 
In addition to physical parameters, EVs are known to possess a range of molecular signatures, 
mostly featuring characteristic enrichment patterns in certain proteins and lipids. Since the 
current knowledge of the EV proteome has yet not allowed to determine any EV-specific 
markers, the community rather adheres to experimental guidelines suggesting the verification 
of a relative abundance/depletion of different proteins [100]. To evaluate the composition of 
EV-associated proteins, easily accessible assays such as western blot (WB) and other 
immunoblot methods (e.g. dot-blot [136]) are commonly used. However, the mere probing 
for a selected set of EV markers is increasingly replaced with the employment of high-
throughput proteomic technologies allowing a closer look on the overall EV protein content 
[99,114,137]. The detection of surface markers can also be achieved by flow cytometry 
approaches using multiplex bead-based platform, investigating tens of different surface 
markers simultaneously [122]. 
It is known that the EV membrane composition largely reflects that of its source cell. Yet, 
similarly to the enrichment of certain proteins, distinct lipids (e.g. sphingolipids and 
cholesterol) are still known to be overrepresented [138]. The relatively late discovery related 
to the biological activity of vesicular lipids [139] somewhat delayed the interest in the lipid 
composition of EVs. Presently, more studies employ chromatography and/or mass 
spectrometry based methods to perform solitary lipidomic or combined omics analysis on 
EVs [140,141] and constantly improve our understanding of the molecular composition and 
sorting of vesicular lipidome. 
In addition to proteins and lipids, EVs are also, as aforementioned known to contain nucleic 
acids. The presence of vesicular DNA is largely disputed [129,142] and often considered as 
contaminants in the EV preparations. The EV RNA content is enriched in short molecules 
[143,144] which are either encapsulated in EVs or reside on their surface, where they are also 
considered as an isolation method-derived impurity. Hence, to ensure the reliability of 
downstream EV nucleic acid analysis (e.g. sequencing, microarrays, quantitative reverse 
transcription PCR (RT-qPCR)), enzymatic treatment of the preparations with DNase and/or 
RNase combined with detergent treatments is advised [130]. Nevertheless, considering that 
the relative quantity of a distinct nucleic acid molecule per EV is low and other co-isolates 
such as lipoprotein particles remain untouched by the enzymatic treatment, a reliable 
detection and quantification of EV RNA still remains a challenge. In addition, depending on 
the sample type, the EV preparations contain a combination of DNA and RNA molecules 
affecting the downstream analysis of one or the other. Though a few methods (e.g. Qubit HS 
RNA assay) efficiently discriminate between these nucleic acid types, others (e.g. Nanodrop, 
Agilent Bioanalyzer chips) measure a combination of both, being a subject to fluctuation and 
misinterpretation of the final data. Attention must also be turned to nucleic acid isolation 
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methods as well as deep sequencing protocols allowing a clean preparation of a single nucleic 
acid type, thereby avoiding the acquisition of mixed molecular signatures. 
The small size, heterogeneity and our poor knowledge of EV biology make their 
characterization particularly challenging. The availability of public online databases has 
greatly expanded our understanding of the diversity of EV features. Yet size, morphology, 
buoyant density and surface marker detection are still most commonly investigated 
characteristics. Emerging new methods, among others measuring the optical- and surface 
charge properties or tracking single vesicles [145–147] underpin the progress in EV 
characterization with new exciting techniques yet to be unveiled. 
 
2.4 EV biogenesis and secretion 
The presence of “coagulant material in minute particulate form“ originating from platelets 
was already described in 1967 [14], followed by the description of plasma membrane 
outward budding mechanism a few years later [148]. Based on the current knowledge, this 
biogenesis mechanism is rather attributed to MVs (and apoptotic bodies), whereas the 
classical exosome biogenesis differs considerably from this process and follows the routes of 
endolysosomal recycling pathway [80]. A schematic overview of EV biogenesis is depicted 
on Figure 2. 
 
 
 
Figure 2 - Illustration of EV biogenesis. 
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2.4.1 EVs derived from the endolysosomal pathway  
2.4.1.1 General overview of biogenesis  
The endolysosomal pathway is known to consist of numerous membrane compartments 
responsible for the catabolism and recycling of material retrieved via extracellular 
endocytosis or intracellular autophagy [149,150]. This knowledge was later complemented 
with the observations of Dr. Rose Johnstone, describing the presence and release of vesicular 
structures via late endosomes and  exposing a new role of the pathway in cellular biogenesis 
[15,17].  From then onwards, a number of studies have concentrated on understanding the 
degradation “escape” routes of the endolysosomal system and revealed a number of different 
components responsible for the biogenesis of endolysosomally-derived EVs, commonly 
referred to as exosomes. 
The endocytosis of extracellular material results in the formation of early endosomes, which 
will either be recycled back to the plasma membrane, or mature to late endosomes [149,151]. 
The membrane invagination activity on the late endosome gives rise to the formation of 
intraluminal vesicles (ILVs), forming MVBs which either fuse with the lysosomes to degrade 
the content [150] or will head towards the periphery of the cell, merge with the cellular 
membrane and give rise to exosomes in the extracellular space [149]. 
 
2.4.1.2 Biogenesis pathways 
For exosome biogenesis, mainly two types of pathways have been described: endosomal 
sorting complex required for transport (ESCRT) dependent [152] and -independent pathway 
[153]. The former starts with the initial clustering of ESCRT-0, -I and -II protein complexes 
at tetraspanins-enriched membrane microdomains [154]. These complexes sort 
ubiquitinylated proteins to the endosomal membrane and initiate the formation of 
intraluminal buds. With the involvement of ESCRT-III, the membrane abscission is 
completed resulting in the generation of MVBs containing tens of ILVs [155–157]. 
The involvement of the ESCRT machinery was first found through proteomic studies [158] 
and its role in exosome biogenesis has thereafter been extensively studied. One possible 
mechanism how ESCRT dependent MVB formation can occur was described in a study by 
Baietti et al. [152], outlining how the expression levels of ALG-2-interacting protein X 
(ALIX; ESCRT-III associated protein), syntenin as well as syndecan modulate ILV formation 
and subsequent exosome release. Later, it was revealed that this process is regulated by a 
small GTPase ARF6 (adenosine diphospate-ribosylation ribosylation factor 6) and 
phospholipase D2 (PLD2) [159] and is activated by heparanase,  trimming the heparan sulfate 
chains on syndecans [160]. Studies have also shown a clear linkage between the ESCRT-0 
protein hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) and exosome 
secretion [161,162]. Yet, the production of the aforementioned syntenin exosomes requires 
only certain ESCRT components but is independent of others [152]. Additionally, 
inactivation of four proteins representing different ESCRTs has been found not to inhibit the 
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formation of MVBs [163], suggesting the existence of an alternative, ESCRT-independent 
mechanisms. In the light of the aforementioned, a HRS competing, CD63-dependent 
formation of ILVs was reported [164], indicating to the possible coexistence of mixed EV 
populations in a single MVB. Additionally, higher order oligomerization of membrane 
proteins has been found sufficient for the formation of human immunodeficiency virus (HIV) 
Gag ILVs [165], a mechanism corroborating with data on syntenin exosomes [152], requiring 
syndecan clustering for their biogenesis. 
It has also been observed that the lipid composition of exosomes is remarkably similar to that 
of lipid rafts, showing high enrichment in sphingolipids and cholesterol [138], the latter 
facilitating the budding process by providing proper membrane curvature [166]. The same 
mechanism of action has been described for lipid metabolism enzymes, neutral 
sphingomyelinase [153] and PLD2 [159] that act through generating ceramide and 
phosphatidic acid in the MVB membrane, thereby inducing negative curvature of the MVB 
and favouring intraluminal budding of the limiting bilayer. 
 
2.4.1.3 EV secretion mechanisms 
While most of the MVBs are destined to degradation through fusion with the lysosomes, 
some are directed to the cell membrane to release their content to the extracellular space. 
Their release is believed to be a regulated process requiring specific stimuli. For example, it 
has been proposed that similarly to lysosomal secretion, the intracellular calcium levels could 
play a role in plasma membrane fusion leading to exosome secretion from certain cell types 
[167]. However, the specific fusion machinery remains undefined. Additionally, several 
proteins are suggested to be involved in EV secretion (reviewed in [168]) with small GTP 
binding proteins of the Rab family ( e.g. RAB11 [169], RAB27 A/B [170] and RAB 35 
[171]) being important players in vesicle budding, mobility or tethering to the cell membrane. 
MVB fusion with the plasma membrane is potentially also aided by SNARE proteins [162], 
however the precise mechanisms of action has not yet been verified. 
Accumulating evidence also suggests the presence of MVB subclasses with potential 
differences in their composition and fate [120,172–174]. Certain lipid content has been seen 
as a determinant for MVB subpopulation trafficking. For example, in case of B lymphocytes, 
cholesterol-rich MVBs appear to preferentially be directed towards the plasma membrane for 
subsequent fusion and exosomal release [175].  In contrary, lysobisphosphatidic acid (LBPA) 
a cone-shaped phospholipid which is generally absent on exosomes [138], resides in 
morphologically distinct MVB subpopulations destined for lysosomal degradation [176]. 
Exosomes with different molecular characteristics have also been detected at the basal and 
apical membranes of epithelial cells [177]. This type of intracellular trafficking and secretion 
is potentially modulated by V0-ATPase activity [178], yet the precise molecular mechanism 
of MVB polarized sorting remains to be established. 
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Thus, the secretion of specific MVBs is potentially dependent of several proteins as well as 
lipids. The existence of different MVB subclasses adds an additional layer of complexity to 
exosome biogenesis as these by themselves can contain an intermixed population of ILVs. 
 
2.4.2 Plasma membrane derived EVs 
In contrast to the endolysosomal pathway, subtypes of EVs (apoptotic bodies and MVs) are 
shed directly from the cell membrane. Though the generation of apoptotic bodies via plasma 
membrane blebbing has been known for decades [179] (and will not be discussed further), the 
mechanisms of MV release have just started to be unravelled. As opposed to exosomes, MVs 
arise via direct budding of the plasma membrane through a process that is activated by 
external factors such as extracellular calcium levels [180] and hypoxia [181]. Following 
induction, the calcium-dependent enzymatic machineries rearrange the phospholipids of 
plasma membrane, driving the exposure of phosphatidylserine (PS) on the cell surface. The 
latter causes restructuring of the actin cytoskeleton, a physical bend in the membrane and 
subsequent budding of MVs [182]. Notably, it has been found that the MV biogenesis might 
still take place even if the lipid asymmetry of the membrane does not change [183], 
indicating to a potential role of other lipid domains, such as cholesterol lipid-rafts [184] in the 
process. Recent finding suggests that a change in membrane curvature could also be aided by 
proteins [185]. Namely, the local protein “crowding” has been verified to generate lateral 
pressure through protein-protein interactions, thereby contributing to membrane bending at 
the cell periphery. 
A successful biogenesis also demands well-regulated cytoskeletal dynamics, often mediated 
via RHO GTPases [186,187]. In addition, several alternative budding mechanisms including 
proteins such as ARF6 [188]; ESCRT component TSG101 (tumour susceptibility gene 101) 
together with arrestin domain-containing protein 1 (ARRDC1) [189], myosin-1a [182] and 
hyaluronan [190] have been implicated in the shedding of MVs, illustrating the richness of 
different pathways depending on the cell type and potentially the catalytic purpose that the 
shed MVs serve. 
In summary, based on the current knowledge, multiple pathways seem to be responsible for 
the generation of EVs directly budding from the plasma membrane as well as the ones 
originating from the endolysosomal pathway. Whether there is a coexistence of different 
mechanisms, dependence on the cell type or whether different pathways are responsible for 
the production of distinct MVB, exosome or MV subtypes, is still to be elucidated.  
 
2.5 Composition and loading of EV cargo 
EVs have been recognized as vehicles of intercellular communication containing a significant 
amount of proteins, nucleic acids and lipids. This material largely reflects the molecular 
profile of their source cells and can be transmitted long distances to directly alter the 
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functional state of the recipient. Hereafter, the protein and RNA composition of EVs will be 
discussed in more detail, as the respective biomolecules were of central importance in the 
constitutive papers. 
 
2.5.1 Protein composition of EVs 
Proteins are the major bioactive components of the vesicular cargo, providing the bulk mass 
to density of EVs. The protein-rich composition is often exploited for characterization 
purposes in order to verify the type and purity of EVs. Nevertheless, as no exclusive proteins 
for the verification of exosomes or MVs exist, the enrichment relies on the testing of a 
combination of surface and luminal markers. 
Due to the endosomal origin, almost all exosomes, independently of the cell of origin contain 
proteins related to MVB biogenesis (e.g. ALIX, TSG101, CD63, CD81, CD9) as well as 
membrane transport and fusion proteins (e.g. Rab GTPases, flotillin) [191,192]. These are 
however not exclusive exosome markers and some of them (e.g. CD63, CD81, CD9) are 
regularly also observed in MVs [140]. Due to the cytoplasmic biogenesis of both vesicle 
types, the purity of EV preparations is usually estimated by the depletion of membrane-
binding extracellular proteins (e.g. fibronectin) and cellular proteins originating from the ER, 
Golgi and mitochondrial membranes [100]. Nevertheless, nuclear markers, such as histones 
or ER-derived chaperons (e.g. heat shock proteins (HSPs)) are still frequently detected in 
EVs, potentially aiding the EV-binding to heparin sulphate proteoglycans (HSPGs) or 
reflecting a general physiological phenomenon of tumour-derived vesicles [119,193–196].  
Regardless that the protein content in exosomes and MVs is highly similar, it has been noted 
that the protein patterns of exosomes are more likely to differ from their source cells than the 
components of MVs [140]. Yet, the cargo of MVs still does not seem to be a random 
sampling of cellular components as several proteins such as ARF6 [188] and Rab22 [181] are 
postulated as potential components of the selective recruitment process. The incorporation of 
exosomal protein cargo has been studied more extensively, mostly relating it to the action of 
ESCRT components. The ESCRT machinery is known to detect and sequester 
ubiquitinylated (Uq)  proteins to the endosomal membrane [197]. Even though the majority 
of ILVs with Uq proteins should be directed towards lysosomal degradation [198] ~60% of 
exosomal proteins still possess the degradation signal [199,200], hence making it logical to 
believe that the ESCRT components would be responsible for their enrichment in exosomes. 
Nevertheless,  it has been seen that to a certain extent ESCRT components are unselective to 
ubiquitin binding, and also interact with non-Uq proteins such as transferrin [201]. This 
strengthens later findings that the binding to whichever ESCRT component might be enough 
for ubiquitin-independent cargo sorting [202]. The system becomes even more complex, as 
also the ESCRT components themselves can be Uq. This, however does not seem to be a 
critical aspect for their function, as a protein with a single ubiquitin moiety is sufficient to 
direct its sorting into MVBs [163].  
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Evidence of the involvement of ESCRT machinery in shaping the vesicular proteome can 
also be obtained from RNA inteference screenings, where the knockdown of HRS, TSG101 
and STAM1 (signal transducing adapter molecule 1) affect the targeting of certain proteins to 
MVBs [174]. This supports an earlier study where the depletion of key subunits from the four 
ESCRTs caused perturbation in the MVB biogenesis and also prevented sorting of the 
epidermal growth factor receptor (EGFR) [163]. The involvement of the machinery is further 
supported by the fact that its components are constantly detected in EV preparations 
[140,158,200]. Still, protein cargo sorting is rather an intermixed process as only certain 
ESCRT components are known to affect the loading of a confined pool of proteins, 
suggesting the existence of alternative, ESCRT-independent mechanisms. For example, 
sorting machineries such as tetraspanin-enriched domains have been proposed to modulate 
the vesicular proteome [203]. The latter mechanism being especially intriguing considering 
that tetraspanins interact with a variety of transmembrane and cytosolic signalling proteins 
[204–206] and are highly abundant in exosomal protein profiles.  
Thus, it is evident that the ESCRT machinery is involved in loading of at least certain 
proteins into EVs whereas parallel cargo sorting pathways are likely to contribute. Still, the 
precise loading mechanisms and their extent in shaping the protein signature of EVs remains 
obscure and might depend on the type of cell and/or vesicle being produced. 
 
2.5.2 Nucleic acid composition of EVs 
In addition to proteins, EVs also contain various types of nucleic acid. Findings on DNA 
include the detection of double stranded- and mitochondrial DNA [142,207,208] as well as 
retrotransposable elements [209]. As the presence of encapsulated DNA is still under active 
debate, the nucleic acid content will hereafter focus on different types of RNA and their 
loading mechanisms into EVs. 
EVs incorporate a variety of RNA species including mRNA, transfer RNA (tRNA), 
mitochondrial RNAs (mtRNAs), long non-coding RNA and different types of small RNAs 
(miRNA, small nuclear RNA, small nucleolar RNA) [210–212]. Additionally, vault RNA 
(VT-RNA) an Y RNA fragments and mRNA degradation products have been identified 
[212,213]. Many studies are also reporting a strong predominance of ribosomal RNA (rRNA) 
fragments [214–217], often denoted as impurities in EV preparations. Yet, considering the 
precise cleavage pattern and overrepresentation of certain transcript regions in EVs 
[216,218], biological importance might still exist. 
Packaging of EV RNA is much less understood than the loading mechanisms of vesicular 
proteins. Early studies suggested that the incorporation is a purely passive event [219], 
relating to the co-localization of miRNAs, Trinucleotide repeat-containing gene 6A protein 
(TNRC6A, also known as GW182) and AGO proteins within the MVBs [220]. EV miRNA 
association with RNA-induced silencing complex (RISC) proteins has also been investigated 
later, revealing an active and finely regulated signalling cascade responsible for miRNA 
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sorting via AGO2 [221,222]. The evidence supporting an active cargo loading arouse from in 
silico analysis [223] defining  mRNA “zipcodes” which were later verified as YB-1 (Y-box 
binding protein 1) and NSUN2 [tRNA (cytosine(34)-C(5))-methyltransferase] recognition 
sites for exosomal mRNA and miRNA enrichment [224,225].  The presence of a similar 
zipcode has been also proposed for MVs [226], though the sequence is longer (25 
nucleotides) and contains a different core string. The vesicular packaging of miRNAs could 
also be driven by hnRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1), which 
binds to specific “EXOmotifs” (GGAG or CCCU) [227]. Furthermore, other factors such as 
non-templated nucleotides at the 3’ end of the miRNA [219] and ceramide-dependent 
packaging of miRNA have been suggested [228,229]. Non-random miRNA loading 
mechanism is also supported by the poor correlation of vesicular and cellular miRNA profiles 
(for some cell lines), the overrepresentation of certain miRNA molecules in EVs and altered 
levels of specific miRNAs in the serum of diseased individuals (which cannot be explained 
by pure passive secretion) [217,230,231]. Yet, some reports rather support passive secretion, 
indicating that the endogenous levels of natural miRNA targets modulate their secretion into 
EVs [232] and implying that some of the miRNA-binding proteins (e.g. AGO2) are relatively 
depleted in EV preparations [126,220, Paper II]. Thus, the mechanisms of vesicular RNA 
loading are rather inconclusive and suggest that parallel mechanism possibly coexist. 
It has been suggested that the loading of RNA into exosomes starts at the endosomal 
membrane, where the RNA resides due to the membrane affinity determined by the RNA 
hydrophobicity, nucleotide sequence and lipid structure/composition of the site [233–235]. 
Considering the relative depletion of AGO2 in exosome preparations together with the 13-
fold excess of miRNAs as compared to AGO2 [236], the membrane binding of “excess” 
miRNA might be plausible. On the other hand, other RNA binding protein (e.g. 
hnRNPA2B1) could also drive the miRNAs to the lipid raft regions owing to their affinity to 
ceramide-rich regions [227]. In terms of hydrophobicity, several RNAs are known to possess 
modifications (e.g. tRNA isopentenylation [233] and miRNA methylation [237]) which could 
potentially increase their affinity to raft-like membrane regions. Both miRNAs as well as 
tRNA-derived fragments are highly enriched in EV preparations [212,217,238]. Whether the 
hydrophobicity of these RNA stretches is also responsible for their sorting into ILVs or if the 
loading is rather mediated by RNA-binding proteins such as hnRNPA2B1 or YB-1[225] has 
not been fully addressed. 
How exactly the selection and loading of RNA into exosomes occurs, remains debatable. The 
versatility of the proposed mechanisms is implying that the loading could be cell-type, 
physiological condition and even RNA-dependent, all this making it plausible that the 
observed mechanisms may coexist. The wider availability of next generation sequencing 
techniques greatly facilitates nucleic acid research, thus improved understanding of the 
composition and molecular secretion mechanisms of extracellular RNAs into EVs it is well 
on its way. 
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2.6 EV uptake 
In addition to verifying the mechanisms of macromolecule loading, increasing attention is 
paid on EV uptake mechanisms, being of high importance for the development of therapeutic 
interventions. 
2.6.1 Methods to track EV uptake 
The monitoring of EV uptake in vivo generally relies on the exploiting of lipophilic 
fluorescent dyes giving an overall distribution and relative quantification of cell-incorporated 
material [239]. This strategy is however prone to pitfalls including unspecific labelling of 
other membrane limited particles, lateral transfer of the dye between cells and extended half-
life beyond that of EVs [240,241]. Single EVs, on the other hand are commonly tracked by 
surface engineering of EV-enriched markers with fluorescent proteins [147]. However, as the 
heterogeneity of EVs limits the tracking of all vesicle subpopulations by this methodology, 
general membrane labelling strategies using palmitoyl-fluorescent protein fusions have 
successfully been exploited [242]. The latter strategy labels the inner leaflet of the EV 
membrane, hence impact on EV binding and uptake is expected to be minimal. In in vivo 
settings, EV uptake has also been tracked with the Cre-loxP system [243]. Though this 
methodology demands the generation of donor- and recipient reporter cells, it represents a 
highly sensitive approach for tracking the functionality of EVs in physiological conditions. 
2.6.2 Mechanisms and influence of surface molecules 
EV uptake occur via multiple routes, including a direct fusion with the cellular membrane 
[244], as well as EV internalization via lipid raft-, clathrin- and calveolae-dependent 
endocytosis, micropinocytosis and phagocytosis [147,184,245,246]. The exact mechanism 
likely depends on the specific lipid/protein composition of the EVs and cell membranes, the 
local microenvironment (e.g. acidic versus basic) and potentially also on the EV subtype 
[247].  
It has long been postulated that EVs, depending on the composition of their surface 
molecules, possess an inherent cellular homing ability. Implications for such a behaviour 
have been observed with unmodified dendritic cell (DC) EVs (Paper IV) as well as tumour-
derived EVs [248,249], exposing an organotropic behaviour in vivo. Cell-pairing has also 
been noted in vitro (personal communication with Dr. Nicole Meisner-Kober and Dr. Wolf 
Heusermann), nonetheless at times contradicting with the evidence from in vivo screenings 
[250] and thereby indicating to the need of further investigation. 
Various complexes are known to use HSPGs to gain entry to the cell, EVs not being an 
exception [251]. Treating the cells with heparin sulfate (HS) mimetics (e.g. heparin, dextran 
sulfate) has been seen to block EV transfer to recipient cells, whereas the presence of HSPGs 
on EVs has no apparent effect on their internalization [251–254]. Owing to the polyanionic 
nature of HS mimetics, the inhibition of the cell entry is potentially an intermixed process and 
could also include binding to scavenger receptors (SRs). For example, SR-mediated effect 
has been observed for high density lipoprotein (HDL) nanoparticles [250], which in contrast 
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to the competitive binding mechanism of HS, deplete cholesterol from the cell membrane, 
induce SR clustering and thereby inhibit EV uptake. In addition, many studies have reported 
the importance of C-type lectins on EV uptake [255,256]. Importantly, in in vivo context, 
healthy pancreatic tissue near pancreatic ductal adenocarcinoma (PDAC) is known to release 
a specific type of lectin, which binds to tumour-derived EVs (tEV), interferes with  their 
uptake in vivo and inhibits metabolic changes in cancer cells [250]. Moreover, protein and 
integrin signatures are known to be important for EV uptake [248,257,258], illustrating the 
variety of molecules potentially affecting internalisation of EVs to recipient cells. 
2.6.3 Factors influencing EV uptake in vivo 
Despite a lack of understanding on the secretion and uptake mechanisms of physiologically 
produced EVs, it is evident that these processes are finely regulated to evade systematic 
clearance of naturally produced EVs. Yet, due to the complexity of monitoring EV secretion 
and uptake in physiological settings (e.g. using xenografts), a great majority of in vivo studies 
are based on exogenously produced vesicles. The curiosity in vesicle in vivo uptake 
mechanisms and surface molecules has largely been driven by the therapeutic potential of 
EVs, as by modulating EV trafficking, one could enhance targeted biomolecule delivery or 
block the transfer of EVs carrying malignant features. 
Intravenously administered EVs have an in vivo half-life between 2 minutes to 24 hours  
[259–263]. In the body, the EVs are constantly patrolled by a network of cells constituting the 
MPS, the system responsible for detecting and clearing foreign material. The scope of this 
clearing machinery can be illustrated by the common biodistribution pattern of exogenously 
administered EVs, which follow a signatory MPS clearance with EV accumulation in spleen, 
liver and lungs [259,262,264]. The extent by which tissue resident macrophages clear 
systemically injected EVs is impressive, as macrophage-depleted mice are able to clear only 
< 2% of EVs as compared to control animals [265]. Similarly to liposome clearance 
[266,267], MPS elimination pattern can potentially be attributed to SR activity [268], 
representing one of the mediators of EV uptake, as discussed earlier. The blockade of SRs 
with dextran sulfate has been shown to decrease liver uptake, significantly increase the 
amount of circulating EVs in plasma and promote vesicle accumulation in breast cancer 
tumours [269]. The SRs on the surface of macrophages may also become activated by the 
exposed  PS on the outer leaflet of the EV membrane [270–272]. Owing to the membrane 
curvature, the enrichment of PS might only be apparent and result from the high membrane 
curvature of the vesicles, rendering two thirds of the lipids to be placed in the outer leaflet 
[273]. Though contradicting thoughts about the precise exposure time, mechanism and 
physiological purpose of PS in the EV membrane remain (reviewed in [273]), PS is known to 
play a key role in phagocytosis and could thereby also affect the circulation time of EVs in 
the body.  
Another major factor affecting the uptake and biodistribution of exogenous EVs is vesicle 
aggregation. This can arise from high g forces used in the ultracentrifugation-based protocols 
or result from EV enrichment methods affecting the natural surface signature of the vesicles 
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(e.g. protein corona [274]), leading to decreased molecular shielding and aggregation of EVs 
[114]. The aggregation is known to modulate the EV uptake routes, cause notable differences 
in the biodistribution and from a therapeutic point of view, could decrease the efficacy of the 
preparation [114]. It has also been suggested that EVs can aggregate in the biological fluids 
due to calcium-mediated cross-linking of PS, similarly to observations with liposomes [275], 
to my present knowledge, studies exploring this possibility on EVs have thus far not been 
conducted. To (re)shield the EV surface, polymers such as PEG can be exploited [275]. The 
hydrophilicity and biocompatibility of PEG make it an excellent tool to simultaneously 
decrease vesicular aggregation and increases EV circulation half-life by shielding them from 
interactions with plasma proteins. Nevertheless, due to the physical blocking of protein-
protein interactions, PEG might dampen the EV-mediated response, unless surface-extended 
targeting moieties are employed [275]. 
The body is a rather hostile environment for exogenously administered EVs with a multitude 
of clearance mechanisms preventing the vesicles from reaching its target. Only through 
obtaining a detailed knowledge of the physiological EV uptake and clearance mechanisms in 
vivo, one would be able to hijack the inherent pathways and aid the progress of EV-mediated 
therapies. 
 
2.7 Biological role of EVs 
EVs have been found in all analysed biological fluids and in the conditioned medium of 
cultured mammalian cells [276–278]. Nonetheless, the universal cellular secretion of EVs 
extends far beyond eukaryotic multicellular organisms, also covering simple organisms such 
as bacteria and archaea [279,280] and thereby suggesting an evolutionarily conserved 
mechanism of cellular communication [281]. 
2.7.1 EVs from prokaryotic organisms 
Though this review concentrated on EVs derived from mammalian (mostly human) cells, it is 
important to note that the production of EVs already existed in prokaryotic organisms. 
While EV secretion by archaea has been studied relatively little, these organisms are known 
to secrete membrane vesicles of 50-230 nm in size, originating from the cytoplasmic 
membrane [282,283]. The precise role of archaeal EVs has not been fully elucidated, 
nevertheless EVs from monoderm archaea are known to convey antimicrobial activity by 
carrying proteins which inhibit the growth of related archaea species [279,282]. Moreover, 
the molecular content of EVs from the archaea family Thermococcales also includes DNA 
[284]. Considering the extreme conditions these hyperthermophilic archaea live in, the 
vesicles provide an excellent protection for the nucleic acid against thermodenaturation and 
furthermore, similarly to eukaryotes, mediate its transfer between different archaea species 
[283]. Interestingly, also archaea possessing a double membrane secrete EVs and are often in 
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close association to other organisms, making it possible that the secreted vesicles deliver 
essential components (e.g. lipids) between the two symbionts [285]. 
In bacteria, EVs act as potent virulence factors [284]. By containing DNA, toxins, 
immunomodulatory compounds and adhesins, bacterial outer membrane vesicles (OMVs) are 
known to contribute to the colonization and successful transmittance of virulence factors to 
the host organism. Notably, the production of EVs by bacteria is not only limited to infection, 
but also carries on during and after the transition to bacterial biofilms [286]. There, the 
vesicles contribute to the biofilm nucleation, nutrient acquisition, defence and bacterial 
communication, thereby serving as potential targets to therapeutic interventions. EVs 
containing DNA, RNA and proteins have also been isolated from bacteria in the natural 
environment, such as the marine ecosystem [287], where the vesicles act as an organic carbon 
source to other marine bacteria, serve as external protein receptors to tackle phage infection 
or again, plausibly constitute vectors for horizontal gene transfer. Hence, most the basic 
biological mechanisms attributed to vesicles date back further beyond the arrival of 
eukaryotes, which nonetheless have attained a spotlight in EV research and will be discussed 
hereafter. 
2.7.2 EVs from eukaryotic organisms 
The initial lack of interest in EVs was dependent on the knowledge which considered them as 
means of disposing unwanted material from cells. 40 years after their initial discovery, the 
vesicle field was rediscovered thanks to the work of Raposo et al. [18] describing the 
communication between B cell-derived EVs and T cells and indicating to the functional role 
of EVs in cell-to-cell communication. From then onwards EVs have been purified from 
different eukaryotic organisms including plants (e.g. carrots, ginger, lemon, grapes, 
grapefruit, watermelon and olive pollen grains [288–293]), fungi [288] and animals [294–
296]. In plants, EVs have been shown to mediate interspecies communication for example by 
modulating the expression of genes such as anti-inflammatory cytokines that are crucial for 
maintaining intestinal homeostasis [289,290] or transferring cross-kingdom dietary miRNAs 
[291]. In fungi, similarly to bacteria, the EVs are known to mostly transport virulence 
associated components [297–299], enhancing pathogenesis even across the blood-brain-
barrier [291]. Most of the vesicular studies concentrate on EVs from animals, especially 
humans and common model organisms such as mice with the bulk number of studies being 
performed in cell-cultures [112]. Due to the variety of EV origins, the discussion of their 
biological roles is unfortunately out of the scope of this review and will instead give a brief 
overview of the role of EVs derived from mammalian, mostly human and mouse cells. 
EVs have been isolated from a range of body fluids including, among others, blood 
components, saliva, amniotic fluid, breast milk and urine [276,278,300]. Their role in the 
body includes a range of physiological processes such as fertilization, development, tissue 
regeneration, stem cell maintenance and immunomodulation which are all achieved by 
protein interactions with cell surface receptors and delivery of bioactive RNA-, protein- and 
lipid cargo (reviewed in [301]). These features are also exploited by EVs derived from 
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diseased cells, such as tEVs which use the potency of vesicular signalling to promote immune 
escape, stimulate growth and support disease spreading, thereby serving as good candidates 
for therapeutic interventions [302]. 
EVs play and important role already at the early stages of development. At fertilization, EVs 
are known to promote sperm-egg fusion [303] and thereafter modulate migration and 
implantation of the early embryo [304]. Subsequently, thanks to the encapsulated 
morphogens (e.g. Wingless (Wnt) and Hedgehog) EVs play an active role in establishing the 
body plane and tissue organization and thereafter support the physiological processes 
throughout the lifecycle of the organism [162,305]. 
One of the most widely explored fields of EV communication relates to various functions of 
the immune system. For example, the role of EVs has been implicated in the induction of T-
cell activation and differentiation modulation towards T helper 1 phenotype, thereby 
enhancing in vivo immunogenicity [306–308]. EVs also aid in maintaining an immune-
privileged site at pregnancy by suppressing T-cell signalling components  [309], mediate 
immune activation in response to allogeneic organs and tissues [310] and participate as pro-
inflammatory mediators in the pathophysiology of arthritis [311], preeclampsia [312] and 
sepsis [313]. Tumour cells are known to secrete anti-inflammatory tEVs by carrying ligands 
which induce T-cell apoptosis or suppress their cytotoxicity and thereby facilitate the 
generation of tumour-promoting immunity [314]. Interestingly, the treatment with anticancer 
drugs induces the secretion of tEVs carrying HSPs, which in contrast are able to generate 
CD8+ T-cell and/or natural killer cell dependent antitumor effect [315,316]. Apart from 
immunomodulation, tEVs play an important role in the generation of an extended tumour 
microenvironment by stimulating angiogenesis, promoting cell migration and inducing 
vascular leakiness [317,318]. All these processes modulate the local physiological conditions 
for tumour thriving and furthermore, aid its dissemination, again with the help of tEVs that 
pre-condition distant sites for metastatic lesions [41,319,320].  
The majority of the aforementioned biological roles of EVs depend on the interactions 
between the vesicular and cellular macromolecules, mostly proteins. Protein transfer in 
physiological settings has been implicated in a recent study investigating the tissue crosstalk 
of EVs during exercise, showing that physical exercise provokes the secretion of EVs with 
altered protein cargo which is mostly directed to the liver [321]. Notably, these proteins also 
included several novel candidate myokines, providing evidence of a new mechanism of 
myokine secretion. Owing to the high efficiency of this macromolecular communication 
system, vesicular trafficking also affects the course of pathogenesis for many diseases. For 
example, EVs have been implicated in the progression of several neuronal conditions like 
Alzheimer’s disease and Parkinson’s disease by spreading pathogenic proteins α-synuclein 
[322] and amyloid-β [323,324].  
The list of functions attributed to EVs also includes the encapsulation and delivery of nucleic 
acids. As the majority of vesicular RNA content does not exceed 200 nucleotides [143,144], 
many of the physiological roles are related to the transfer effects of short RNAs, especially 
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miRNAs. For instance, the majority of miRNA in blood is known to originate from adipose 
cells and circulates in association with EVs [325]. Some of these miRNAs have been shown 
to play an important role in metabolism regulation by improving glucose tolerance via gene 
expression modulation in liver via fibroblast growth factor 21 (Fgf21) [325]. Furthermore, 
EVs derived from adipose tissue macrophages are able to transfer insulin resistant traits from 
obese subjects to lean mice by carrying miR-155 which contributes to the phenotypic changes 
[326].  According to recent studies, EV miRNAs are also means of controlling the ageing of 
stem cells, directing the balance of cellular differentiation, inducing cellular repair programs 
and repressing apoptotic genes [327–331]. At the immune synapse, T cell-derived EVs 
release vesicles that contain miRNA and are able to modulate gene expression in antigen 
presenting cells (APCs) [303]. The exchange of miRNA cargo has also been noted between 
DCs and DC EVs [303] as well as regulatory and helper T cells [303]. MiRNAs in tEVs are 
known to promote tumour progression by modulating metabolism and immune response, 
promoting angiogenesis,  inducing metastasis and conferring resistance to therapy [332–338]. 
The role of many other EV RNA species such as tRNA fragments, Y RNAs, circular RNAs 
and long noncoding RNAs (lncRNAs) has been less studied and their physiological role is yet 
to be established. Nevertheless, EV associated lncRNAs have been implicated in the 
enhancement of cell viability, tumour growth and progression [339,340], tRNA halves in 
maintaining stem cell potency to differentiation [341] and Y RNA fragments in 
cardioprotection via modulation of interleukin-10 (IL-10) expression [213]. 
The fact that all cells tested from the three domains of life produce EVs indicates to their 
indispensable role in supporting physiological processes. Different cell types are continuously 
exchanging EVs over short and long distances in vivo, making it a rich source of information 
for the surveillance of health and disease and serving as basis for therapeutic interventions. 
 
2.8 Therapeutic potential of EVs 
Owing to the surrounding lipid bilayer, the content of EVs is well protected from nuclease 
and protease degradation, enabling long distant transport of macromolecules to exert remote 
extracellular communication. Though this could also be achieved by other delivery vehicles, 
such as liposomes, EVs hold features that stay beyond the reach of synthetic carrier systems, 
such as native biological components serving as a rich source of intrinsic therapeutic and 
biomarker-based potential. Potentially more importantly, they have an intrinsic ability to 
cross several biological barriers that their synthetic counterparts are unable to do. 
The first reports describing the potential of EVs in ameliorating diseased conditions arose 
from studies employing the conditioned medium (CM) of hypoxic MSCs to relieve acute 
myocardial infarction [342,343]. Thereafter, many studies have employed the inherent 
therapeutic potential of MSC EVs to treat a variety of conditions including therapy-refractory 
graft-versus host disease (GvHD), radiation damage and kidney injury [92,128,344–347]. The 
healing potential of MSC EVs has been postulated emanate from the delivery of 
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proteins/RNA to promote angiogenesis and suppress apoptosis, generation of energy needed 
for cell survival  and immunomodulatory properties [253,347–349]. The administration of 
stem cell-derived EVs has been confirmed safe in humans as well as in all tested animal 
models [128,344,350–352], yet clinical results in humans have only been conducted on two 
instances [128,350]. Currently, allogenic unmodified MSC EVs from cord blood are 
undergoing Phase II/III clinical trial of Type-1 diabetes (NCT02138331), but the results of 
that trial are yet not published. Considering the successful employment of MSC-derived EVs 
in experimental animal models, more trials are expected in the near future. 
Another vesicle source often used in therapeutic setting is DCs, which are commonly used for 
the generation of EV-based cancer vaccines. For example, tumour-associated antigen pulsed 
DC EVs have been used in cancer immunotherapy against non-small-cell lung cancer 
[353,354], colorectal cancer [355] as well as metastatic melanoma [356], all these clinical 
studies implicating to a safe and well-tolerated T-cell mediated antitumor response. In other 
settings, vesicle-based vaccines have been derived from bacteria and yeast cells [357,358]. 
Wild type OMV-based vaccines from bacteria were developed already more than 20 years 
ago [359] and are known to exhibit a remarkable immunomodulatory potential. Though no 
fungal vaccines have yet reached to the clinic, currently four licensed OMV vaccines from 
Neisseria meningitidis serogroup B are available [357,359,360]. 
In addition to vaccines, EVs have gained increasing interest as vehicles for nucleic acid 
delivery. Due to the inefficient loading of larger stretches of RNA [361], the majority of 
studies rather exploit the therapeutic potential of short RNA molecules. For instance, MSC 
and fibroblast EVs loaded with short RNAs against oncogenic KRAS have been reported to 
efficiently target pancreatic cancer in multiple mouse models and significantly increase the 
overall survival of the animals [362,363]. The potential of EV miRNAs also arises from 
studies showing that EV-encapsulated miRNAs are able to enhance the therapeutic effect of 
MSC EVs in ameliorating liver fibrosis [364], inhibiting myeloma-related angiogenesis [365] 
and supporting liver protection in experimental autoimmune hepatitis [366]. Similar 
therapeutic effect has been achieved by using EVs loaded with mRNA/protein. An interesting 
solution to antitumor therapy was reported by Mizrak et al. [367] where MVs were 
engineered to carry a suicide gene mRNA/protein which was able to convert a nontoxic 
prodrug 5-fluorocytosine to an anticancer agent 5-fluorouracil and thereby efficiently induce 
tumour regression upon systemic treatment with the prodrug.  
Irrespective of the efficiency of the bioactive RNA molecule, it is of utmost importance that 
the majority of the cargo reaches to the site of interest. To escape the highly efficient EV 
clearance mechanisms in vivo, EV surface has been modified with PEG molecules or ligands 
such as CD47, which acts as a “don’t eat me“ signal for phagocytic cells and enhances EV 
circulation half-life in blood [362,368]. The therapeutic effect of EV-loaded cargo can further 
be improved by modifying the repertoire of surface molecules. Though the employment of 
targeting moieties is often not necessary to gain a biological effect, surface engineering 
strategies greatly reduce off-target events and enhance uptake specificity. Surface 
modification of EVs has for example been used to target EGFR expressing breast cancer cells 
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with let-7a miRNA [263] and to direct vesicular siRNA delivery to the brain by using  rabies 
virus glycoprotein (RVG)-targeted EVs [79]. Avoiding off-target effects is especially 
important for some synthetic drugs, such as chemotherapeutic agents. By employing an 
arginine-glycine-asparagine targeting peptide, doxorubicine-loaded EVs have been reported 
to selectively accumulate in breast cancer xenografts and reduce tumour growth [369]. At 
times, chemotherapeutics (doxorubicin, curcumin or paclitacel) have also been transferred via 
untargeted EVs resulting in successful inhibition of cancer growth and amelioration of septic 
shock in mouse models [369–373].   
In addition to targeted therapeutics, EVs could be employed as diagnostic (and prognostic) 
biomarkers. The largest medical area possibly benefiting from EV-based non-invasive 
disease monitoring relates to cancerous conditions. Altered expression patterns of several EV 
miRNAs are known to contribute to the pathogenesis and metastasis of a range of tumours 
[334,374–381] as well as to neurological disorders [338,382]. Specific protein composition of 
EVs has also been associated with the transfer of metastatic potential to non-cancerous cells 
and plausible serves as a determinant of metastatic organotropism [41,248,319]. As many 
cancers are not easily accessible for histological analysis, the sampling of EVs and profiling 
of their macromolecule content allow non-invasive diagnostics for primary tumours, 
metastasis, cancer relapse as well as response to therapy [383,384]. Currently, implications 
for EV miRNA-based prognostics have only been reported for prostate- and ovarian cancer 
[375,377]. 
The natural therapeutic properties together with infinite opportunities of EV modifications 
have paved the way for an explosive interest in EVs as biomarkers, gene expression 
regulators and macromolecular drug delivery vehicles. The progression from bench to 
bedside is somewhat hampered due to the lack of standardization in isolation and 
characterization methods as well as insufficient knowledge about their in vivo biodistribution, 
stability and clearance. Additionally, sufficient expertise on their biological role is still 
needed before translation into clinics can be achieved.  
 
2.9 EVs versus synthetic lipid-based delivery systems 
Lipid-based delivery systems have been employed for drug delivery already for decades  
whereas the employment of EV-based therapeutics in clinical setting is still in its infancy 
[385]. Both of these delivery systems share a range of common features in their composition, 
uptake and biodistribution as well as exploit common methodologies for isolation and 
characterization. Despite the high resemblance to one another, these natural and synthetic 
vesicles have a range of dissimilarities which could be exploited to further improve both 
systems. 
Lipid-based formulations are the most studied for drug delivery with numerous approved 
products mostly to deliver chemotherapeutics [386,387]. The number of clinical studies 
performed with cell-derived EVs is much more sparse and clinically approved EV-
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therapeutics do not yet exist [351,388]. One of the major hurdles in translation of EVs to 
clinical use is the development of well-controlled, standardized, high-yield production, which 
is achievable for synthetic vehicles, such as liposomes [389], but considerably more complex 
in case of biological systems [389]. Apart from that, EV-based therapeutics are often difficult 
to define in terms of the mode of action underlying the suggested effect. This results from the 
highly complex macromolecule composition of EVs, serving as a rich source of therapeutic 
potential, yet making it virtually impossible to define and constantly reproduce the set of 
active components. Such hurdles are largely unfamiliar to highly defined synthetic carriers, 
which however could greatly benefit from molecular characteristics of EVs to improve their 
performance. 
Despite the synthetic or natural origin of the aforementioned carriers, both delivery systems 
can be considered as nanoparticles allowing many of the technologies that have been in use 
for lipid-based delivery systems (liposomes) to also be exploited in EV research. This applies 
for example to the generation of artificial EVs via extrusion through filters or by using 
microfluidic system [370,390]; purification methods such as ultrafiltration, UC and SEC 
[114] as well as to analytical methods measuring the size, surface charge and concentration of 
the nanoparticles [391]. Similar lines in the two carrier systems can also be seen in the range 
and strategies of cargo loading. Both EVs and liposomes are lipid bilayered vesicles with an 
aqueous core, serving as a suitable environment for the encapsulation of hydrophilic small 
molecules as well as macromolecules, as already discussed. The encapsulation of 
hydrophobic molecules is somewhat more difficult for EVs [392], whereas the preparation 
procedure of synthetic liposomes seems tailored for such purpose, allowing integration of 
hydrophobic cargo into the bilayer during assembly [389]. In terms of cargo loading 
strategies, some loading (e.g. endogenous overexpression and microfluidic mixing) are 
characteristic to natural or synthetic nature of the nanoparticles and can therefore not be 
cross-applied. On the other hand, simple co-incubation with the cargo of interest can be used 
for both EVs and liposomes [371,393,394].  
In addition to various similarities in the range and strategies in cargo loading, EVs and 
liposomes are both amenable to modifications that allow the cargo to reach its target in a 
more specific manner. Whereas EVs already hold a wide selection of surface molecules, 
potentially acting as combinatorial targeting moieties, liposomal surface ligands need to be 
selectively tailored for the purpose. In return, liposomal formulation procedure allows 
controlling the affinity, avidity as well as receptor density on the surface [395]. This makes 
targeted liposomal delivery more predictable than the transfer via EV-mediated systems, 
which suffer from heterogeneity and undefined representation of the ligands [396]. It has 
been observed that in head-to-head studies liposomes often succumb to EV-mediated delivery 
[264,394,397].  Yet, many studies seem to lack fair grounds for the presented comparisons as 
the liposomal formulations are often inadequately chosen or poorly described [396]. Hence, 
the potential superiority of EVs over synthetic carriers perhaps cannot be ascertained as the 
benefits of both systems are highly dependent on the macromolecule and disease context. 
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Despite apparent differences in the abundance, complexity and pattern of surface molecules, 
these ligands affect the in vivo fate of both liposomes as well as EVs. For example, one of the 
lipid components of EVs, PS is commonly employed also in liposomal formulations and 
might partially determine the circulation half-life of both nanoparticles. Physiologically, PS is 
known to trigger phagocytosis of apoptotic cells, and as illustrated by the biodistribution 
pattern of both EVs and liposomes, also acts as a mediator of MPS-driven nanoparticle 
clearance, rendering the majority of the material to accumulate in liver and spleen [259,398–
400]. This accumulation pattern could in part also be attributed to the similar size range of 
EVs and liposomes, where smaller particles (up to 100 nm) accumulate in the liver and larger 
ones (> 200 nm) are removed from the circulation by splenic filtration [401,402]. 
Nevertheless, lipid composition and size represent just a part of the biophysical properties 
that liposomes and EVs hold, as also surface charge, -hydrophobicity and protein 
composition are major effectors of successful delivery. 
In order to evade clearance by biological surveillance mechanisms, the surface of liposomes 
is often modified by PEGylation [403].  Coating with polymers has successfully also been 
applied for EVs and provided an effective means of prolonging circulation time in vivo [368]. 
EVs are postulated to also escape clearance owing to the highly heterogeneous protein 
decoration, simultaneously promoting extended circulation time and acting as ligands to 
enhance specific uptake by target cells [399]. Liposomes, in contrast, generally do not have 
surface proteins or possess only one specific targeting ligand, limiting the variety of specific 
ligand-receptor interactions and often forcing them to solely rely of surface PEGylation to 
avoid removal from circulation.  
The benefit of using biological systems as delivery vehicles includes their high versatility in 
the diversity and characteristics of natural molecules. This heterogeneity serves as an inherent 
source of potential therapeutics, yet makes it often hard to define and reproducibly generate 
the active component in the future. Liposomes represent a more controllable system in terms 
of their size, composition and biophysical properties, yet suffer from the lack of innate 
combinatory targeting potential and higher toxicity. An increased understanding of the 
components and gateways that EVs use for signalling and cell entry would hence open new 
avenues for the delivery of bioactive cargo which could be hijacked by lipid-based delivery 
systems offering a defined environment for the biologics. 
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AIMS  
Lipid-based delivery vectors are one of the most widely exploited nanoparticles for the 
encapsulation of nucleic acids. This thesis firstly investigates the nucleic acid delivery 
potential of synthetic cationic lipid-based nanoparticles and thereafter concentrates on the 
composition and content dynamics of their natural counterparts, EVs, in order to shed light on 
the potential of lipid-based entities for therapeutic nucleic acid delivery. The individual 
objectives of the constituent papers were set to serve the wider aim of this thesis and are the 
following: 
3 Paper I 
 To evaluate the extent by which cryo-manipulation affects the nucleic acid delivery 
efficiency of cationic lipid-based reagents. 
 To shed light on the mechanisms contributing to the elevated potency of the cryo-
manipulated formulations. 
 To understand the applicability of freeze-thawing on the delivery potential of a wider 
range of commercial formulations.  
 
4 Paper II 
 To investigate the cell line dependant differences in the small RNA and protein 
composition of EVs. 
 To examine the interplay of vesicular RNA and protein content with a special focus 
on RNA/miRNA binding proteins and the respective RNA species. 
 
5 Paper III 
 To investigate the overall small RNA content in EVs and non-vesicular secretome. 
 To verify the extracellular profile and quantity of secretory miRNAs at their basal 
level as well as upon genetic overexpression. 
 To describe the differential sorting patterns of secretory miRNAs and their 
importance to the biological activity of EVs. 
 
6 Paper IV 
 To investigate how the dose and route of administration affects the biodistribution of 
EVs in vivo. 
 To investigate cell source dependent tissue distribution and inherent homing capacity 
of EVs. 
 To explore the effect of a targeting moiety on the general EV biodistribution and local 
accumulation to the tissues of interest.  
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METHODOLOGY 
7 Methodological considerations 
Detailed descriptions of the employed methodologies can be found in the constitutive papers. 
The following chapters aim to give a concise overview of the most important materials and 
methodologies used. 
 
7.1 Cell sources  
HEK293T (human embryonic kidney cells), Neuro2a (mouse neuroblastoma cells), human 
spinal muscular atrophy fibroblasts (GM03813), HepG2 (human hepatocellular carcinoma 
cells),  C2C12 (immortalized mouse myoblasts) and hTERT-MSCs (human telomerase 
reverse transcriptase immortalized bone marrow mesenchymal stem cells) [404] were 
included in Paper I to evaluate the nucleic acid delivery efficiency of synthetic lipid-based 
transfection reagents. The small RNA and protein content of EVs (Paper II) was investigated 
in HEK293T, RD4 (human skeletal muscle cells), Neuro2a, C17.2 (immortalized mouse 
neural progenitor cells) and C2C12 cell lines.  Paper III focused on human derived cell 
sources and exploited the fractionation of the extracellular material derived from HEK293T 
cells and hTERT-MSCs. Paper IV employed the conditioned medium of murine bone 
marrow derived DCs (strain C57BL/6J), hTERT-MSCs, rat oligodendrocytes (OLN-93), 
C2C12 cells and mouse melanoma cells (B16F10) to evaluate the in vivo biodistribution of 
EVs in C57BL/6J mice. The culturing conditions of the aforementioned cell types are 
outlined in the respective papers. 
 
7.2 EV enrichment techniques 
Paper II and IV include ultracentrifugation as the chosen method for EV enrichment. Briefly, 
the cell culture CM was first subjected to differential centrifugation steps whereby the 
clearance of floating cells and cell debris was achieved at 300 × g and 2000 × g, respectively. 
Thereafter, in order to enrich for smaller vesicles the supernatant was cleared through 0.22 
µm filter followed by pelleting of the EVs at ~120 000 × g and a subsequent wash spin of the 
phosphate buffered saline (PBS) reconstituted pellet at 120 000 × g. The final EV pellet was 
brought to a desired volume with PBS. In order to allow improved fractionation of the 
extracellular secretome in Paper III, we employed size exclusion liquid chromatography 
methodology[114]. The workflow included the aforementioned differential centrifugation 
steps as well as a 0.22 µm filtration step, resulting in cell culture media largely deprived of 
larger particles. The cleared CM was then ultrafiltrated by using 100 kDa MWCO filters 
(Amicon, Merck Millipore) at 3500 × g. The resulting retentate was loaded onto HiPrep 
16/60 Sephacryl S-400 HR column (GE Healthcare, PA, USA) by employing the ÄKTA 
pure/prime chromatography system (GE Healthcare, PA, USA) equipped with a 280 nm UV 
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detector. The EV and non-vesicular samples were pooled based on the resulting absorbance 
profile and concentrated using the 10 kDa MWCO Amicon Ultra spin filters (Merck 
Millipore). In order to cover a wide range of extra-vesicular material, the non-vesicular 
sample also included the flow through from the 100 kDa ultrafiltration step. 
 
7.3 Nanoparticle characterization  
7.3.1 Nanoparticle Tracking Analysis 
To measure the size distribution and concentration of particles, all constitutive papers 
employed Nanoparticle Tracking Analysis (NTA) on the NanoSight NS500 instrument 
(Malvern Ltd, UK) equipped with a 488 nm laser and a 500 nm long pass filter. The specific 
settings in terms of camera gain, shutter setting and detection threshold are described in the 
individual papers. Generally, five 30-60 seconds long videos per sample were recorded and 
analysed with NTA 2.3 analytical software (Malvern Ltd, UK). For the quantitation of 
fluorescent particles, the sample was under a constant flow in order to decrease the bleaching 
of the fluorescent signal.  
7.3.2 Western blot 
The EVs in Paper II, III and IV were evaluated for the enrichment of EV markers with WB. 
Briefly, an equal number of particles (5E9-1E10) were mixed with the sample buffer 
containing 0.5M dithiotreitol (DTT), 0.4 M sodium carbonate (Na2CO3), 8% sodium dodecyl 
sulfate (SDS), 10% glycerol and thereafter heated at 65ºC for 5min. The cell samples were 
scraped from 2D cell culture plates, counted for viability with Trypan Blue Exclusion test 
(Thermo Fisher Scientific, MA, USA), pelleted and lysed with an appropriate volume of 
radioimmunoprecipitation assay (RIPA) buffer, kept on ice and vortexed every 5 min for half 
an hour. Subsequently, the samples were spun at 12 000 × g for 12 minutes at +4ºC; the 
supernatant was collected, mixed with the sample buffer and heated as described above. The 
samples were run on NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen, Life Technologies) at 
120V and transferred to an iBlot nitrocellulose membrane with the iBlot system (both 
Invitrogen, Life Technologies). The membranes were blocked with Odyssey blocking buffer 
for 60 minutes at room temperature with gentle shaking. Thereafter, the membranes were 
probed with primary antibody solutions described in the respective papers, followed by 
IRDye 800CW and 680LT secondary antibody solutions (LI-COR Biosciences, NE, USA). 
Between the aforementioned steps, the membranes were washed every 5 min for half an hour 
with washing buffer (1 × PBS with 0.1% Tween 20; Sigma Aldrich, Saint-Louis, MO, USA). 
Washing steps including a final rinsing of the membrane with 1 × PBS were also performed 
before imaging. The membranes were visualized on the Odyssey infrared imaging system and 
further analysed by using Image Studio Lite Version 5.2 (both from LI-COR Biosciences, 
NE, USA). 
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7.3.3 Total Internal Reflection Fluorescence Microscopy 
The physical characteristics of lipoplexes in Paper I were evaluated with Total Internal 
Reflection Fluorescence (TIRF) microscopy on a Zeiss Laser TIRF 3 system (Carl Zeiss AG, 
Germany).  The deposition of Alexa-568-labeled duplex RNA complexes with freeze-thawed 
or non-frozen LF2000 (Thermo Fisher Scientific, MA, USA) on P35G-1.5-14-C glass inserts 
(MatTek Ashland, MA, USA) were recorded at 37 °C in preheated Opti-MEM Reduced 
Serum medium (Thermo Fisher Scientific, MA, USA). The time dependent complex 
deposition on the glass surface was expressed as increase in the relative fluorescence over the 
basal background. 
7.3.4 Transmission Electron Microscopy 
TEM was utilized to characterize the lipoplexes in Paper I as well as EV morphology in 
Papers II, III and IV.  In all cases, 2% uranyl acetate solution (Sigma-Aldrich, Saint-Louis, 
MO, USA) was used to stain the material spotted onto glow discharged electron microscopy 
grids. In some experiments of Paper I, a biotinylated nucleic acid (Label IT Nucleic Acid 
Labelling Kit, Biotin, Mirus Bio LLC) and 10 nm colloidal gold labelled neutravidin were 
used to visualize the formed complexes for their identification. The imaging was performed 
by using a FEI Tecnai G2 Spirit BioTWIN microscope (FEI, OR, USA) run at 120 kV (Paper 
I), with a FEI Tecnai 10 TEM (FEI, OR, USA) at an accelerating voltage of 100 kV (Paper II, 
III) or JEOL 1010 TEM (JEOL, Peabody, MA, USA) (Paper IV). 
 
7.4 Methods to evaluate nucleic acid loading and delivery 
efficiency 
7.4.1 Luciferase assay 
Transfection efficiencies of different synthetic delivery vectors in Paper I were assessed by 
using the Luciferase Assay System (Promega Corporation, WI, USA) and luminescence of 
firefly luciferase was measured with GloMax-96 Microplate Luminometer (Promega 
Corporation, WI, USA). When applicable, the luciferase activity was further normalized to 
the amount of total protein in each sample, as measured by a Protein Assay (Bio-Rad 
Laboratories, Hercules, CA). 
7.4.2 RT-qPCR 
Paper I and III included RT-qPCR analysis to either determine the potency of nucleic acid 
delivery vehicles or quantify the miRNA content of the secretory fractions. In Paper I, the 
recipient cells (HeLaLuc705[405]) were treated with splice-correcting minicircle plasmids or 
oligonucleotides to restore the correct splicing and generate a functional firefly luciferase in 
the aforementioned reporter cells. In Paper III, RT-qPCR was employed to either monitor the 
mature miRNA level of overexpressed let-7a and let-7b in the different fractions of the 
HEK293T secretome or to quantify the basal expression of a selected set of miRNAs in 
HEK293T and hTERT-MSC EVs and non-vesicular fraction. In both papers, total RNA was 
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extracted following the standard phenol-chloroform extraction protocol by using either Trizol 
or Trizol LS solutions (both from Thermo Fisher Scientific, MA, USA) followed by cDNA 
synthesis using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, CA, 
USA). U7asLuc705 small nuclear RNA and small nucleolar RNA C/D box 24 (RNU24) 
quantitation were performed using the Custom TaqMan Small RNA Assays and TaqMan Fast 
Universal PCR Master Mix No AmpErase UNG (Applied Biosystems, CA, USA) according 
to the manufacturers’ instructions. The miRNA quantitation in Paper III was performed by 
using the TaqMan Gene Expression Master Mix together with the respective TaqMan 
MicroRNA Assays (both from Applied Biosystems, CA, USA). All the samples were run on 
the Step-One Real-Time PCR instrument (Thermo Fisher Scientific, MA, USA). The cycle 
threshold (Ct) values were obtained from the StepOne Software (Applied Biosystems, CA, 
USA); the PCR efficiency of each reaction was calculated with LinRegPCR program[406] or 
obtained from the StepOne Software. ΔΔCt (Paper I) or efficiency (E)^-Ct (relative to cel-
miR-39 RNA extraction control level; Paper III) methods were used to express the levels of 
the targets under study. 
 
7.5 Next generation sequencing of small RNAs 
7.5.1 Sample preparation and sequencing 
Paper II and III include small RNA sequencing of cells, vesicles and non-vesicular secretome. 
The RNA from the aforementioned samples was extracted by following a standard phenol-
chloroform extraction protocol using either Trizol or Trizol LS solutions (both from Thermo 
Fisher Scientific, MA, USA). Improved RNA precipitation was gained by adding 2 µl of 
PolyAcryl Carrier PC 152 polymer (Molecular Research Center Inc., OH, USA) per reaction. 
The RNA integrity of the cell samples was verified on Bioanalyzer RNA 6000 Pico Total 
RNA Kit (both Agilent Technologies, UK) and the RNA concentration for all samples was 
measured with the Qubit 2.0 Fluorometer by using the Qubit RNA HS Assay Kit (Thermo 
Fisher Scientific, MA, USA). Either 60 ng (Paper II) or 250 ng (Paper III) of total RNA was 
subjected to small RNA library preparation by using the NEBNext Multiplex Small RNA 
Library Prep for Illumina (NEB, MA, USA) kit according to the manufacturer’s instructions. 
The barcoded samples were size selected on a 6 % Novex TBE PAGE gel (Thermo Fisher 
Scientific, MA, USA), the fragments corresponding to microRNA range were cut out and 
subjected to purification with the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel, 
Germany). Thereafter, the products were quantified by using the KAPA Library 
Quantification Kit (Kapa Biosystems, UK) and pooled at equimolar ratio. In Paper II, two 
libraries (technical replicates) were generated in parallel, each eventually containing a pool of 
12 barcoded samples. In Paper III, 18 barcoded samples (biological replicates) were pooled. 
In both cases, the readymade libraries were checked on the High Sensitivity D1000 
ScreenTape (Agilent Technologies, UK) and quantified using the KAPA Library 
Quantification Kit (Kapa Biosystems, UK) to enable precise loading of the flow cell. The 
clusters were generated by using the cBot and sequenced one replicate per lane on either one 
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(Paper II) or two (Paper III) flow cells on the HiSeq2500 (Illumina Inc., CA, USA) with a 
1x51 setup in RapidRun mode. 
7.5.2 Data analysis 
Small RNA sequencing data was analysed in a similar manner for both Paper II and Paper III. 
Briefly, raw sequencing reads were quality controlled by FastQC [407] analysis and 
subjected to adapter removal by Cutadapt/1.9.1 [408]. All reads with an adapter and a length 
of 17-35 bases (filtering with BBMap release 35.40 [409]) were subjected to subsequent 
mapping on the Ensembl 38.85 releases of the mouse and the human genome by using 
Bowtie1 (release 0.12.6) [410] in -v1 alignment mode and best alignment stratum reporting 
option. Annotation was performed in a stepwise manner with HTSeq (release 0.6.1) [411] in 
stranded mode by following a stepwise annotation procedure allowing the discrimination of 
‘small RNAs’, followed by ‘ribosomal RNA’ and ‘other RNAs’. Gene biotype classification 
followed the classification details in Vega Genome Browser release 68; details of the 
included RNA biotypes can be found in Paper II. The annotations of different RNA biotypes 
were retrieved from miRBase  release 21 [412], Ensembl 38.85 [413], piRNAbank [414] and 
UCSC Table Browser hg38/mm10 entries [415]. 
For data visualization, MultiQC v1.3 [416] and the online analysis software Morpheus 
(available from the Broad Institute; https://software.broadinstitute.org/morpheus; Paper II) as 
well as Multiple Experiment Viewer (Version 4.9.0) [417] and R-studio software [418] (R 
version 3.4.2; Paper III) were used.  Differential expression analysis of miRNAs was 
performed by using the R package DESeq2 [419]. All statistical analyses (except for 
differential expression statistics) were performed using GraphPad Prism Version 6 or 7 
(GraphPad Software, Inc., CA, USA). 
 
7.6 Proteomic analysis 
The proteomic analysis of EVs in Paper II exploited liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) as described previously [114]. The analysis covering Gene 
Ontology (GO) term enrichment  and -overrepresentation was performed by using the Protein 
ANalysis THrough Evolutionary Relationships (PANTHER) software [420]. In addition, the 
study included an in-depth analysis of the ‘RNA binding’ proteins (GO:0003723), obtained 
via the QuickGO browser (http://www.ebi.ac.uk/QuickGO/) and Vesiclepedia [421] database. 
The list of ‘miRNA related’ proteins was created by manual curation of the ‘RNA binding’ 
proteins. All proteomic analysis was based on unique protein identifiers, thereby taking into 
account different protein isoforms. 
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7.7 In vivo techniques 
7.7.1 In vivo delivery of nucleic acid complexes 
In Paper I, in order to evaluate the potency of LF2000 lipoplexes, 5 µg of firefly luciferase 
expressing plasmid (PT2/C-fluc plasmid; Addgene plasmid 20203; Addgene, MA, USA) was 
used either on its own, or complexed with 12.5 µg freeze-thawed or non-frozen LF2000. The 
complexes were formed in OptiMEM serum free medium and a total volume of 50 µl was 
used for contralateral intramuscular (i.m.) injections in mice. The luminescence was imaged 
24 hours post-injection using the IVIS Imaging System (PerkinElmer, MA, USA).  
7.7.2 Tracking and tissue distribution of EVs 
Paper IV assessed the tissue distribution of EVs from different cell lines using intravenous, 
intraperitoneal or subcutaneous injection to NMRI or C57BL/6 mice. In order to track the 
EVs in vivo, a near-infrared fluorescence dye, DiR (1,1-dioctadecyl-3,3,3,3-
tetramethylindotricarbocyanine iodide; D12731, Invitrogen, Life Technologies) was used. To 
label the EVs, the filtered CM was co-incubated in the presence of 1 µM of DiR at room 
temperature for 15 minutes. Thereafter, the EVs were purified by following the EV 
enrichment protocol by UC, as described above. The same procedure was employed for 
unconditioned medium, serving as the control to determine the extent of unspecific tissue 
distribution. The biodistribution of the EVs was evaluated with the IVIS Imaging System 
(PerkinElmer, MA, USA) with or without organ dissection. The dosage of EVs was based on 
NTA particle quantification and was optimized within the study to 1E10 particles/gram of 
body weight in order to ensure sufficient fluorescence detection and minimal signal saturation 
in the investigated organs. The tissue distribution of CD63-eGFP positive EVs in explanted 
organs was also evaluated immunohistochemically. 
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RESULTS AND DISCUSSION 
8 Paper I 
Paper I outlines the effect of cryo-manipulation of a cationic lipid-based formulation, 
LF2000, which, after being frozen and thawed, showed orders of magnitude higher nucleic 
acid delivery in vitro and in vivo than the non-frozen counterpart. 
The preliminary observations of the increased potency were made with luciferase-encoding 
plasmid delivery. As a result, a log-scale improvement in nucleic acid transfection efficiency 
throughout eight different cell lines, including hard-to-transfect cells such as human 
fibroblasts and mouse myotubes, was observed. The effect was most prominent at lower 
nucleic acid doses and was witnessed with different batches of LF2000. To better quantify the 
cell viability as well as the number of cells with successful plasmid delivery and expression, 
we employed flow cytometry analysis. These results further confirmed the significantly better 
performance of freeze-thawed LF2000 over non-frozen with up to 45% increase in the 
number of transfected cells. A decrease in cell viability with flow cytometry as well as cell 
proliferation assay (WST-1) was observed at the highest plasmid concentration for the freeze-
thawed formulation. Yet, this was valid only for Neuro2a cells. 
To exclude the possibility that the potency was a result of a specific plasmid, expression 
cassette and/or type of promoter used, the non-frozen and freeze-thawed LF2000 were tested 
in a splice-correction assay using U7 snRNA construct [422] or different splice-correcting 
oligonucleotides in a HeLa Luc 705 cell line [405]. Consistent with the previous results, cells 
transfected with freeze-thawed LF2000 displayed significantly higher luciferase signals than 
those transfected with non-frozen reagent, confirming that the effect was consistent 
regardless of the plasmid organization or the chemical composition of the nucleic acid. 
As it is known that conditions optimized for in vitro transfections are often not applicable to 
efficient in vivo delivery [423], we further evaluated whether freeze-thawing of LF2000 has 
an impact on nucleic acid delivery in vivo. Indeed, i.m. injection in mice of a luciferase 
plasmid complexed with non-frozen or cryo-manipulated LF2000 confirmed the in vitro 
results where a log-scale higher luminescence in the muscle treated with freeze-thawed 
reagent was observed. 
We next became interested whether the effect could persist over a longer period of time 
and/or could be obtained by other ways of cryo-manipulation. After overnight freezing, 
thawing and storage for two weeks+4ºC the reagent still showed improved transfection 
efficiency over non-frozen LF2000. Repeated freeze-thawing cycles and snap-freezing in 
liquid nitrogen also exhibited higher transfection efficiencies than the non-frozen counterpart. 
Yet, the best overall potency was seen with the reagent that was used immediately after 
overnight freezing. 
By studying the physical characteristics of non-frozen and freeze-thawed LF2000 complexes, 
we saw that the latter formed a much more heterogeneous population of particles, with a 
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slightly smaller size, yet with no apparent differences in their morphology or nucleic acid 
release potency. Nonetheless, by exploiting TIRF microscopy, we observed that the freeze-
thawed complexes dispersed more readily on a glass surface and sedimented to a higher 
degree than the non-frozen LF2000. These properties are likely to underlie the increased 
cellular uptake of freeze-thawed LF2000 lipoplexes as well as elevated cellular activity. 
To find further explanations to the phenomena, we explored the effect of freeze-thawing on a 
handful of other lipid-based and non-lipid based transfection reagents. As a result, we saw a 
similar increase in transfection efficiency for Lipofectamine RNAiMAX reagent, allowing us 
to speculate that the outstanding transfection efficiency relates to the specific structure or 
composition of both Lipofectamine products. 
In conclusion, this study reveals that simple cryo-manipulation is able to significantly 
increase the nucleic acid delivery potency of a commercial cationic lipofection reagent and is 
likely to be applicable for an even wider range of lipid-based delivery agents. Importantly, 
our results illustrate that freeze-thawing allows to drastically reduce the amount of 
transfection reagent needed for cellular transfection, while retaining the desired activity. 
 
9 Paper II 
EVs mediate their native biological effects by transferring or displaying their cargo to target 
cells. While certain broad-spectrum EV mediated effects reflect their protein cargo 
composition, others have been attributed to individual EV-loaded molecules such as specific 
miRNAs [338,424]. In this work, we investigated the cell line dependent differences and 
interplay of small RNA and protein cargo in unmodified EVs. 
Firstly, we performed small RNA sequencing on UC-purified EVs as well as their source 
cells of human (HEK293T, RD4) and mouse (C2C12, Neuro2a and C17.2) origin. By size-
selecting the libraries and length-restricting data analysis to sequences of 17–35 nucleotides 
in length, we were able to see that the majority (~80%) of the cellular RNA did represent 
“small RNA” sequences, of which a great majority (73-93%) represented miRNAs, 
confirming the reliability of the applied methodology. Across different cell lines, the EVs had 
considerably less miRNA and more sequences derived from piwi-like RNA (piRNA) loci 
than their source cells. Hierarchical clustering analysis of miRNA signatures revealed that all 
the EV samples clustered together with their parental cells as opposed to EVs from other cell 
sources. Though the number and relative expression of EV miRNA sequences was in good 
correlation with the cellular background, for piRNA sequences, no clear correlation between 
the vesicular and cellular expression level was found. Due the lack of proof of the association 
of piRNA sequences with piRNA proteins, together with the evidence of a relative scarcity of 
characteristic piRNA features (e.g. length of 27-35 nucleotides, 5’ uracil bias), these RNA 
stretches rather represent sequences derived from piRNA loci than bona fide piRNAs.  
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Though, as mentioned earlier, the majority of cellular sequences represented “small RNAs”, 
it is noteworthy to mention that the “small RNA” content of EV samples was highly variable 
across the tested cell types. On average only ~22% of the sequences were derived from 
“small RNA” loci, while the reads derived from rRNA loci were more prominent and covered 
36-94 % of all annotations in EVs. In addition, both cells and EVs had a large number of 
tRNA and Y RNA sequences, corroborating with earlier EV-based studies also employing 
short read-length sequencing [212,217,238,425]. For all RNA categories (“small RNAs”, 
“rRNAs” as well as “other RNAs”), a small number of highly abundant sequences covered 
the bulk RNA content within each category, illustrating the relatively low diversity of the 
RNA mass. The prominence of individual RNA species was explicitly evident from the list of 
overall top-ranking RNA genes, where the EV samples were dominated by highly abundant 
“rRNA” and “other rRNA” sequences, whereas the cells samples were rather enriched in 
miRNAs.  
Next, we set out to explore whether the EV proteome, particularly the repertoire of RNA-
binding proteins would correspond to our observations about the RNA species in EVs. This 
part of the study was performed on HEK293T and C2C12 EVs given their disparate ‘small 
RNA’ (and thus also miRNA) content. In both proteomes, we detected ~2000 proteins, of 
which ~60% overlapped with entries in the Vesiclepedia database [421]. Similarly to 
transcriptomic results in which a relatively small number of RNA sequences contributed to a 
large proportion of total detected RNA reads, a small number of highly abundant proteins 
(~200 identifications) covered the bulk content (~75%) of both EV proteomes. Also, in line 
with the finding of a high abundance of ribosomal, coding and tRNA fragments in the 
sequencing, we discovered high levels of rRNA-, poly(A)- and tRNA binding proteins in the 
proteomic datasets of both EV types. GO analysis revealed that ~20-30% of the identified 
proteins in EVs were “RNA binding” (GO:0003723), correlating well with the mean reported 
frequency (21 %) of RNA binding proteins in Vesiclepedia database [421]. Similarly to the 
results of the bulk proteome, the “RNA binding” proteins that contributed most to the EV 
proteome described poly(A)- and rRNA binding proteins, double- and single-stranded RNA 
binding proteins as well as translation-related protein sets.  
In order to further understand which RNA-binding protein classes are represented in the data 
sets and how these correspond to the small RNA sequencing results, we created a custom 
curated GO list of “miRNA related” proteins. Thereby, we were able to define that ~1 % of 
the HEK293T and C2C12 EV proteins were relevant to the molecular function, biological 
processes or cellular components of miRNAs. Most of them represented proteins with very 
low expression level, resulting in their contribution to the total EV protein mass by only ~0.9 
% for both samples. Though C2C12 EVs were substantially richer in miRNAs than 
HEK293T EVs, we were unable to detect any major differences in the miRNA-related 
proteome, precluding us from further speculations of whether specific miRNA binding 
proteins drive the miRNA sorting into EVs. In addition, even though EVs showed a high 
number of piRNA sequences, we were unable to detect any “piRNA binding” proteins, 
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aligning well with our observation that the sequences annotated as piRNAs in this study 
rather represent reads mapping to piRNA loci. 
In conclusion, this study investigated the vesicular RNA and protein cargo composition and 
interplay in a handful of cell types. The present data is particularly useful for future work in 
unravelling the biological mechanisms underlying vesicular RNA and protein sorting and 
serves as an important guide in developing EVs as carriers for therapeutic RNA interventions.  
 
10 Paper III 
Proceeding from the results of Paper II, we became increasingly interested in exploring the 
wider composition of the cellular secretome and decided to concentrate more on the specific 
miRNA profiles. To look into the composition of the EV secretome as well as investigate the 
non-EV material, we decided to exploit SEC [114] enabling to discriminate and fractionate 
both secretory portions. 
Owing to earlier reports [105,107], it is known that a large amount of miRNA is secreted 
outside of EVs. To investigate by which extent miRNAs of interest get released to the 
extracellular space, we transiently overexpressed pri-let-7a and pri-let-7b in HEK293T cells, 
and quantified respective mature miRNA levels in the secretome. As a result, we could see 
that upon overexpression the amount of non-EV miRNA exceeds tens of folds the miRNA 
level seen in the EVs. Though similar evidence has already been seen by centrifugation-based 
studies [426,427], we hereby provided additional insights and profiled the miRNA abundance 
across the secretome. 
Given the log-scale differences in the miRNA amount between the EV and non-EV fractions, 
we became interested whether the global pool of miRNAs follows a similar secretion profile. 
The subsequent small RNA sequencing analysis was performed on the HEK293T cells and 
hTERT-MSCs as well as their EV and non-EV secretory fractions, separated identically to 
the preliminary overexpression studies. 
When looking in detail into the small RNA secretome, the bulk secretory material consisted 
predominantly of miRNAs and piRNA-like sequences. The total miRNA efflux to the 
extracellular environment was comparable for EVs and non-EV samples. Also, we observed 
that the expression levels of EV-, non-EV and cellular miRNAs were well correlated, apart 
from some DE miRNAs in the EVs and non-EV fraction, which exceeded several fold the 
levels in their source cells. Irrespectively, a vast majority of all the DE hits represented 
miRNAs with relatively low expression in both the source cells as well as in the secretory 
fractions, fitting with the correlation of the samples’ miRNA levels, indicating that the bulk 
of the secretome does rather resemble the cell of origin and suggesting that the majority of the 
miRNA follows a passive secretion mechanism. 
To reflect on the total miRNA content of the secretome, we decided to quantify the total 
amount of candidate miRNAs in the EV and non-EV fractions by using RT-qPCR from an 
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equal volume of starting material. As a result, we could see that the total amount of non-
vesicular miRNA exceeded tens to hundreds of folds the basal miRNA amount in EVs. 
Taking into account the distinct miRNA quantities at their basal level in both secretory 
fractions, above 90% of the total extracellular miRNA got secreted to the non-vesicular 
fraction, coinciding with our preliminary observations of overexpressed non-EV miRNA 
levels. 
In summary, this study outlines that the bulk miRNA content in cells, EV and non-EV 
fraction is highly alike, whereas the majority of DE miRNAs represent low-abundant 
molecules and miRNAs both at their overexpressed and basal level are predominantly found 
in the non-EV portion of the secretome. This information is valuable in order to gain a 
thorough understanding of short RNA sorting mechanisms into EVs and thereby progress the 
employment of EVs as therapeutic nucleic acid carriers. 
 
11 Paper IV 
In order to develop EVs as carriers for therapeutic RNA interventions, it is of utmost 
importance to have a clear understanding of their body-wide distribution. Thus, Paper IV was 
brought about to gain a comprehensive overview of the biodistribution of exogenous EVs, its 
dependence on the administration route, cell source, dosing as well as on the potential of 
targeted tissue distribution. 
Firstly, in order to track the EVs in vivo we set out to validate the labelling of EVs 
incorporating the near-infrared lipophilic dye (DiR). Lipophilic DiR dyes are known to 
possess a low level of autofluorescence, give high fluorescence output once incorporated in 
membranes and offer good tissue penetrance owing to their near-infrared spectrum. Yet, the 
incorporation of unbound dye into cell membranes as well as its transfer between neighboring 
cells results in unspecific fluorescence events [428], emphasizing the need of proper 
background controls. To evaluate the performance of the labelling strategy, the labelling of 
DiR EVs was evaluated against a free DiR dye control on a density gradient separation. As 
expected, the free DiR dye displayed a lower buoyant density and fluorescence than the DiR 
labelled EV samples, indicating the presence of free dye, devoid of lipid membranes. The 
density and fluorescence profile of DiR labelled EVs across the gradient as well as the co-
localization of EV marker ALIX indicated successful labelling. After UC purifying the DiR 
labelled unconditioned medium and additional monitoring of free DiR dye in vivo, we could 
confirm that any excess dye would be lost during EV isolation, allowing us to proceed with 
the chosen labelling strategy. 
In order to see whether and how the dose could affect the distribution of exogenous EVs, we 
conducted a dose titration study; 0.25 × 1010 - 1.5 × 1010 particles per gram (p/g) of body 
weight were intravenously (i.v.) injected into mice, followed by organ harvesting 24 hours 
post-injection. Notably, even though at increasing doses the overall tissue distribution pattern 
did not change, the relative fluorescence values in the liver were decreased. This was 
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interpreted as a potential saturation of the MPS, leading us to choose the intermediate dose of 
1.0 × 1010 p/g for subsequent experiments. 
Due to employment of lipophilic EV labelling strategy, we also evaluated the kinetics of EV 
biodistribution in order to rule out the tracking of free- as opposed to EV-bound DiR dye and 
found that the overall biodistribution up until 24 hours remained largely unchanged. Yet, we 
did observe an initial pulmonary accumulation of EVs at 5 minutes post-injection, plausibly 
representing the primary exposure of administered EVs to the capillaries of the lung. At the 
48 hours’ time point we observed increased changes in the tissue distribution profile (e.g. 
high accumulation in pancreas), potentially representing EV redistribution events, a later EV 
uptake phase or an artefact due to the long half-life of the dye [240]. 
The most common administration route for EV-based in vivo studies is i.v. injection. Yet, it is 
important to assess how different administration routes affect the distribution of EVs as well 
as whether different routes can be used to boost a desired therapeutic outcome. To estimate 
the effect of EV administration routes, we investigated the biodistribution differences 
between i.v., intraperitoneally (i.p.) and subcutaneously (s.c.) injected vesicles. Thereby, we 
could see that the i.v. injected EVs accumulated significantly more in the liver and spleen as 
opposed to i.p. or s.c. injected EVs. The s.c. route also resulted in significantly lower 
fluorescence values in the ex vivo imaged organs, plausibly indicating to the retention of EVs 
in the adipose tissue. These results highlight the importance of the choice of EV 
administration route in order to either obtain a favourable biodistribution pattern or a desired 
pharmacokinetic profile. 
The intrinsic tissue tropism of EVs has been a matter of intense debate in the field. To 
explore the organotropic preferences, we investigated the biodistribution patterns of EVs 
derived from 3 mouse (C2C12; B16F10; primary immature bone-marrow derived DCs), 1 rat 
(OLN-93) and 2 human cell types (HEK293T; primary human MSCs) 24 hours post i.v. 
injection. Generally, the highest accumulation of EVs was seen in liver, followed by spleen 
and lungs. Yet, the distribution pattern of DC EVs deviated significantly from this 
accumulation profile, exhibiting strong fluorescence from the spleen and weak signal from 
the liver as compared to other tested EV sources. Considering earlier reports dissecting the 
integrin-dependent EV organotropism [248], we hypothesize that the observed distribution 
pattern could also be caused by a unique repertoire of molecules displayed on the surface of 
DC EVs. In light of a great potential of EV tropism for targeted therapies, further studies are 
needed to unravel the extent and specific mechanisms of the phenomenon. 
Lastly, to evaluate the impact of EV surface engineering on targeted tissue delivery, we 
employed DC-derived EVs expressing a chimeric Lamp2b-RVG on their surface. RVG is 
known to bind to the acetylcholine receptors [429] and enhance brain targeting of EVs, as 
evidenced by earlier studies [79]. Indeed, a small, but significant 2-fold increase in the brain 
accumulation of targeted EVs was detected thereby leaving the overall biodistribution of EVs 
largely unaltered. This exemplifies the sensitivity of the EV labelling strategy employed 
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throughout the study as well as indicates the potential of using targeting moieties on the EV 
surface. 
In conclusion, this study showed that DiR labelling is a suitable methodology for tracking 
EVs in in vivo assays with high specificity and sensitivity. In addition, even though the 
majority of EVs accumulate in liver and spleen, the distribution pattern could be affected by 
the cell source, administration route, dose and the presence of targeting moieties on the EVs. 
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